Insights into the molecular determinants involved in *Mycobacterium tuberculosis* persistence and their therapeutic implications

Hemant Joshi, Divya Kandari, and Rakesh Bhatnagar

Molecular Biology and Genetic Engineering Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India; Amity University, Rajasthan, Jaipur, Rajasthan, India

ABSTRACT

The establishment of persistent infections and the reactivation of persistent bacteria to active bacilli are the two hurdles in effective tuberculosis treatment. *Mycobacterium tuberculosis*, an etiologic tuberculosis agent, adapts to numerous antibiotics and resists the host immune system causing a disease of public health concern. Extensive research has been employed to combat this disease due to its sheer ability to persist in the host system, undetected, waiting for the opportunity to declare itself. Persisters are a bacterial subpopulation that possesses transient tolerance to high doses of antibiotics. There are certain inherent mechanisms that facilitate the persister cell formation in *Mycobacterium tuberculosis*, some of those had been characterized in the past namely, stringent response, transcriptional regulators, energy production pathways, lipid metabolism, cell wall remodeling enzymes, phosphate metabolism, and proteasome protein degradation. This article reviews the recent advancements made in various *in vitro* persistence models that assist to unravel the mechanisms involved in the persister cell formation and to hunt for the possible preventive or treatment measures. To tackle the persister population the immunodominant proteins that express specifically at the latent phase of infection can be used for diagnosis to distinguish between the active and latent tuberculosis, as well as to select potential drug or vaccine candidates. In addition, we discuss the genes engaged in the persistence to get more insights into resuscitation and persister cell formation. The in-depth understanding of persistent cells of mycobacteria can certainly unravel novel ways to target the pathogen and tackle its persistence.

CONTACT Rakesh Bhatnagar, rakeshbhatnagar@jnu.ac.in

Molecular Biology and Genetic Engineering Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction

Tuberculosis (TB) remains a serious human health problem caused by *Mycobacterium tuberculosis* (*M. tb*). According to the annual Global TB reports, nearly 10 million people got infected with the disease in 2019, and 1.2–1.3 million infected people died [1]. The current therapeutic regimen of tuberculosis includes a combination of four drugs, namely, isoniazid, rifampicin, ethambutol, and pyrazinamide, for a minimum of six months, which is extendable up to nine months in cases of latent bacilli [2]. Although the recommended TB treatment kills most of the drug-susceptible tuberculosis bacteria, a subpopulation remains able to tolerate this long course of treatment. Two key reasons for the failure of therapeutic programme are: the long duration of the treatment and the presence of a large number of asymptomatic TB carriers (Latent TB patients). The dormant or persistent bacteria are believed to switch to an active form whenever the conditions are favorable due to the weakened immune status of the host and are primarily liable for the recalcitrance of mycobacterial infection [3,4]. Persisters are basically the phenotypic variants to wild type bacterial populations that are slow-growing, transiently tolerant to high doses of antibiotics, and may reactivate the TB infection after cessation of the antibiopic treatment [5,6]. Besides, under antibiotic stress conditions also, the number of persistent bacteria increases, which may be the prominent reason for the failure of the clinical treatment. Despite several efforts and recent advancements in the arena of drugs and therapeutics, there is no drug available that can target the persistent bacteria due to a lack of comprehensive understanding of the molecular mechanism of persistence and reactivation [7]. However, existing studies indicate that persisters arise either stochastically or in response to *in vitro* environmental stress, which mimics the *in vivo* granuloma environment the bacteria encounter during infection [8].

Interestingly, the mechanisms of persister formation via stochastic gene expression or environmental stresses are different. One good example of stochastically induced persistence in *M. smegmatis* to isoniazid where a stochastic decrease in the expression of KatG, an enzyme required for the conversion of isoniazid prodrug to its active form results in the reduction of the effective concentration of the active drug for action, leading to increased tolerance to the drug [9,10]. On the other hand, environmental stress induces a bet-hedging persistence in the preexisting persisters in a bacterial population, which means under stressful conditions, heterogeneity arises in terms of the underlying persister phenotype. Increased tolerance to ciprofloxacin in *E. coli*, a DNA gyrase inhibitor, happens when DNA damage induces TisB expression and the resulting decrease of proton motive force leads to a state of dormancy [10,11].

Further, understanding the molecular mechanisms that control the formation of persisters and their resuscitation has remained elusive. In this review, we describe a comprehensive overview of the *in vitro* stress models that mimic the *in vivo* conditions to identify the molecular determinants of *M. tb* crucial for survival in adverse conditions. Moreover, in-depth information about the genes involved in *M. tb* persistence will pave the way in identifying novel drug or vaccine targets and will help in the eradication of tuberculosis infection by targeting both latent and active *M. tb* and shortening the duration of tuberculosis treatment. Finally, we will briefly discuss the recent developments in drugs and vaccines that target latent mycobacteria to control TB infection.

Various stress models for studying *M. tb* persistence

Upon infection into the host, *M. tb* encounters stressful conditions like low oxygen availability, acid stress, nutrient deprivation, and oxidative stress. To gain an insight into the expression of *M. tb* genes against these host-derived stress conditions, *in vitro* stress models that could imitate the *in vivo* stress conditions of infection (as shown in Table 1) along with transcriptomics and whole-genome sequencing approaches are being used by researchers worldwide [7]. The putative candidate genes derived from these approaches are then investigated for their possible involvement in the persistence of *M. tb*. In previous studies using these *in vitro* stress models (Figure 1), putative genes correlated with persistence were predicted but, only a subset of those genes were experimentally proven to be involved [12,13]. Therefore, these models require significant upgrading for them to be employed to understand persistence.

Nutrient starvation model

This model mimics a condition of the persistent state of *M. tb* and thus assists in investigating the significance of nutrient availability in granuloma and its effect on *M. tb* persistence. Initially, Loebel et al. (1933) devised this model wherein bacterial cultures were transferred
Table 1. Various stress models generated to study the M. tb persistence with their detailed information.

| S. no. | Stress model                  | Type of model | Description                                                                 |
|--------|-------------------------------|---------------|-----------------------------------------------------------------------------|
| 1.     | Nutrient starvation model     | In vitro      | Gene expression profiling of an exponential-phase culture of M. tb starved in phosphate-buffered saline for 96 hours. |
| 2.     | Hypoxic Wayne model           | In vitro      | Gene expression profiling of M. tb exposed to the intracellular fraction extracted from activated bone marrow-derived macrophages (BMMs). |
| 3.     | Drug persistence model        | In vitro/Ex vivo | Differential gene expression analyses of M. tb under different growth conditions including exponential phase, stationary phase, and non-replicating persistence phase. |
| 4.     | Lysosomal in vitro exposure   | Ex vivo       | Gene expression profiling of M. tb exposed to the lysosomal fraction extracted from activated bone marrow-derived macrophages (BMMs). |
| 5.     | Lipid-rich (cholesterol and fatty acid) environment model | Ex vivo | Gene expression profiling of M. tb under different growth conditions including exponential phase, stationary phase, and non-replicating persistence phase. |

Later this model was modified such that there was cessation of M. tb replication and the transcriptomic profile at 96 h revealed that 279 genes were upregulated and 323 genes were downregulated. Furthermore, the downregulated genes were found to be related to energy metabolism, lipid biosynthesis, amino acid synthesis, translation and posttranslational modifications, DNA replication, and virulence, which is quite in tune with the long-term persistence observed in M. tb. Later, Jamet et al. (2015) observed that under nutrient starvation conditions stringent response got activated to regulate the genes of mycolic acid biosynthesis (i.e., hadABC) that may facilitate the adaptation of M. tb to persist for longer periods.

**Hypoxic Wayne model**

The Wayne model could mimic the "hypoxic TB granuloma environment" through a gradual decrease in oxygen conditions, hence also known as the gradual hypoxic model. In this model, the bacteria are at a non-replicating and low metabolic activity state to persist for longer duration. The transition from aerobic to anaerobic culture conditions are brought by the transfer of growing M. tb culture to sealed tubes, for creating a hypoxic environment, as through bacterial metabolism occurs a gradual decrease in oxygen levels. Further under these culture conditions a non-replicative persistence (NRP) state, namely, NRP1 (1% dissolved oxygen saturation) and NRP2 (0.06% dissolved oxygen saturation) reaches. Additionally, the comparison of gene expression profiles of stationary phase and non-replicating persistence phase cultures demonstrates numerous genes induced in the NRP compared to 29 genes of the stationary phase. According to recent studies, five genes that are highly expressed in the NRP model, such as Rv0251c, Rv0841c, Rv1874, Rv2332, and Rv2660c, along with Rv3290c (lat) gene that was found to be strongly induced in both stationary and NRP phases. In-depth studies on these results may assist to uncover the bacterial mechanisms for long-term persistence.

**Enduring hypoxic response model**

As the name suggests this model helps investigate the persistently induced genes of M. tb, under consistent hypoxic conditions for a long time. The aerated exponential M. tb culture upon incubation for 4 h, 8 h, 12 h,
96 h, and 168 h under hypoxic conditions is followed by transcriptional profiles at each time point. Remarkably, 230 genes were initially not expressing until late and consistent hypoxic conditions of hypoxia, as after, 96 h and 168 h [20]. Hence, they can be correlated with the induction of late-stage hypoxia. In a previous study, dosR regulon was found to be induced within 2 h of hypoxia to control its initial stage in M. tb [21,22]. Data mining revealed that nearly 47 and 5 genes, induced in this model were common with nutrient starvation and Wayne hypoxic models respectively [16,19]. Precisely, Rv0251c, Rv1805c, Rv1152, Rv2517c, and Rv3290c were conserved in the obtained set of induced genes, among all the three models discussed previously.

**Drug persister model**

To resist the wrath of antibiotics and the host immune system, bacteria evolves different strategies, for instance, an antibiotic-tolerant, persistent subpopulation develops within the bacterial population, but, it is afflicting to have a limited insight about these persister cells. In the drug persister model, an exponentially growing culture of M. tb is incubated with an antibiotic, D-cycloserine, capable of lysing the bacterial cells and used for isolating persister cells. RNA samples from culture aliquots, taken at various times, say, 7 or 14 days for transcriptomic studies. Furthermore, upon transcriptomic profiling, 1408 genes were found to be downregulated and 282 genes upregulated [23]. Thus numerous genes were downregulated and a majority of those were involved in growth and energy metabolism [23]. In-depth analysis suggested that five genes namely Rv0251c, Rv1805c, Rv1152, Rv2517c, and Rv3290c were common among the data obtained from the drug persister model, enduring hypoxic response, nutrient starvation, and Wayne hypoxic models. Later, Torrey et al. (2016) unraveled certain M. tb mutants that had a high persister formation tendency in both *in vitro* cultures and clinical isolates [24]. Upon comparison of these mutants by whole-genome sequencing and transcriptomic analysis from the *in vitro* cultures and clinical isolates, some genes involved in carbon metabolism,
lipid biosynthesis, transcriptional regulators, and toxin-antitoxin system, implying that multiple pathways involve in M. tb persister formation and these high persister forming mutants may furnish in the relapse of tuberculosis infection [24].

The granuloma model
Granulomas are the organized structures formed by infected macrophages and activated lymphocytes. These are the niche of the nonreplicating persistent bacilli where they survive and hide from stressful conditions like hypoxic, oxidative stress, nutrient starvation, and acidic pH. Thus, through ex vivo granuloma model, the host-mycobacterium interactions during dormancy and resuscitation could be understood. Loss of acid fastness, accumulation of lipids, and resistance to anti-TB drugs are the characteristic of M. tb harbored in human granulomas, which can be observed in this model also [25]. In this model, human peripheral blood mononuclear cells (PBMCs) growing in M. tb infected collagen matrix are extracted and incubated for 8 days, during which the lymphocytes aggregate around the infected macrophages to form the microgranuloma structure. Detailed investigations found that the granuloma model better emulates the human TB granuloma by compromising the ability of tgs1 mutants to enter dormancy and lipY mutant to get out of dormancy [25].

LivE model
M. tb adapts and survives within the lysosomes of activated macrophages, but limited information is available regarding the molecular players involved in this survival strategy. The LivE model, also called the Lysosomal in vitro exposure (LivE) model, assists in apprehending this survival strategy. The model includes exposure of M. tb to the soluble fraction of lysosomes extracted from activated murine macrophages [26]. Transcriptomic studies revealed that M. tb incubated with 20 µg/ml of lysosomal soluble fraction for 48 h led to upregulation of 264 and downregulation of 106 genes [27]. Moreover, comparison studies of the transcriptional profiles of LivE model with other stress models led to four genes (Rv2036, Rv1472, Rv0251c, and Rv1956) that were common among the nutrient starvation model, gradual hypoxic model, and the enduring hypoxic response model [27].

Lipid-rich dormancy model
Lipids are crucial for pathogenesis of M. tb during its interaction with the host [28,29]. During infection, M. tb modulates lipid metabolism of itself as well as the host. M. tb induces a low-density lipoprotein response to promote the formation of foamy macrophages to ultimately facilitate the formation of caseous granuloma comprising triglycerides, lactosylceramides, and cholesterol [30–32]. Several in vitro stress models exist but none of them recapitulates the lipid-rich environment that presents within the granuloma. Lipid-rich dormancy model is the recent model developed to mimic the lipid environment present inside the tuberculosis granuloma. In this model, M. tb was separately in vitro cultured in presence of either lipid [33] or dextrose, followed by transcriptomic analysis at exponential phase, stationary phase, and nonreplicating persistence (NRP) phase, under both conditions [29]. The stationary and NRP phases are assumed to be the closest fit with the metabolic state of persistence. Upon differential gene expression analysis in the lipid environment, 368 genes were found, of which 185 genes were upregulated and 183 genes were downregulated [29]. Furthermore, six of them, namely, Rv0678, Rv217c, Rv2393, Rv3159c, Rv3160c, and Rv3161c were consistently expressed among all three phases and thus were designated as “the main core lipid response” set of genes [29].

Functional aspects of genes established in M. tb persistence
As the M. tb cells acquire a persistent state or withstand unfavorable growth conditions, the integrated expression of several different molecular determinants from essential cellular processes, such as virulence, detoxification and adaptation, cell wall and cell process, intermediary respiration, lipid metabolism, and various regulatory pathways are needed. Here we unravel the genes that are experimentally proven (Figure 2) to be involved in the regulation of M. tb persistence, as shown in Table 2 and Table 3.

Intermediary respiration and metabolism genes
icl
Fatty acids and lipids are a significant source of carbon and energy for M. tb while infection as well as in persistence state [34,35]. This is one of the adaptation strategies for the long-term survival of persistent bacteria that enables the metabolic shift of carbon sources to C2 compounds produced by the β-oxidation of fatty acids [36]. Under these
circumstances, the glyoxylate cycle increases significantly as an anaplerotic reaction that allows the C2 substrate to maintain the tricarboxylic acid (TCA) cycle [37]. Isocitrate lyase (Icl) is an enzyme of the glyoxylate cycle that catalyzes isocitrate to succinate and glyoxylate conversion. Expression of the *M. tb* icl gene was increased under oxygen-limiting conditions and during uptake in infected macrophages, suggesting that it may be involved in adaptation to unfavorable conditions favoring persistence in bacteria [38,39]. Deletion of icl gene in *M. tb* had a minor effect on the growth of bacteria in the acute infection phase however in the chronic infection phase the survival and growth of bacteria were severely impaired. The study also revealed that upon infection, the icl mutant of *M. tb* underwent strong attenuation, in activated macrophages, rather than in the resting macrophages [40]. Conclusively, a link could be established between the host immune status and the expression of icl gene in mycobacteria that suggests Icl is needed for the survival of *M. tb* during the persistent phase of infection. It is necessary for the bacterial survival in activated macrophages rather than that in resting macrophages.

**treS and glgA**

The outermost part of the *M. tb* cell wall is capsular, whose 80% extracellular polysaccharide is alpha glucan bound by alpha (1–4 linkage) with branching at every 5 to 6 residues by alpha (1–6 linkage) [41–43]. *glgA* gene encodes alpha-1,4-glycosyltransferase enzyme and the corresponding mutant *glgA* possess low glucan content in the capsule. This mutant was thus unable to persist within the infected mice, indicating that the complete capsule is needed for persistence [44]. Nevertheless, still, no direct evidence connecting the GlgA protein with the persistence of *M. tb*, but still under investigation. Another gene *treS* involved in the synthesis of trehalose from maltose [45]. Trehalose is a significant structural component of the cell wall glycolipid, as it forms trehalose-6, 6’-dimycolate (TDM), which is ester-linked trehalose with two mycolic acid residues [46,47]. TDM has several functions implicated in the *M. tb* pathogenesis such as inhibition of phagosome to lysosome fusion that protects bacteria from acid-dependent macrophage killing [48] and conversion of NAD to NADH that results in the depletion of NAD-dependent enzyme activity during infection [49]. *treS* mutant of *M. tb* upon infection causes enhanced
Table 2. Various genes of *M. tb* that are induced under mentioned stressful conditions and are known to be involved in persistence of the pathogen are listed.

| Rv no. | Gene name | Functional product | Function | Induction conditions | References |
|--------|-----------|--------------------|----------|----------------------|------------|
| **Intermediate metabolism and respiration** | | | | | |
| Rv0467 | icl1 | Isocitrate lyase | Involved in glyoxylate cycle | Low pH, low oxygen, macrophage infections, in vivo TB granuloma conditions | [40,132,149,232] |
| Rv1212c | glgA | Putative glycosyltransferase | Probably involved in cellular metabolism | Low oxygen | [44,70] |
| Rv2780 | aldA | L-alanine dehydrogenase | Involved in cell wall synthesis | Low oxygen, nutrient starvation | [16,55,70] |
| Rv2583c | relA | Probable GTP pyrophosphokinase | Involved in the metabolism of ppGpp | Nutrient starvation, low oxygen | [56,60,61] |
| Rv2109c | pcrA | Proteasome α-subunit | Protein degradation | Reactive nitrogen intermediates, oxidative stress | [66] |
| Rv2110c | pcrB | Proteasome β-subunit | Protein degradation | Reactive nitrogen intermediates, oxidative stress | [66] |
| Rv0363c | fba | Fructose-1,6-bisphosphate aldolase | Involved in glycolysis | Low oxygen, stationary phase, change in carbon source | [69–71] |
| Rv1568 | bioA | Adenosylmethionine-8-aminooxyacetate aminotransferase | Bioconversion of pimelate into diethiobiotin | Stationary phase | [78,233] |
| Rv2436c | nadE | Glutamine dependent NAD synthetase | Biosynthesis of NAD | - | [80] |
| Rv2702 | ppgk | Polyphosphate glucokinase | Phosphorylation of glucose by using polyphosphate or ATP | - | [87] |
| Rv0650 | glkA | Glucokinase | Predicted role in sugar metabolism and regulation | - | [87] |
| Rv1620c | cydC | ATP binding ABC transporter CydC protein | Involved in cytochrome biogenesis | Low oxygen, nitric oxide | [88,89] |
| **Vilirulence, detoxification, and adaptation** | | | | | |
| Rv1126 | treS | Trehalase synthase | Biosynthesis of trehalose | Low oxygen, nutrient starvation, macrophage infection, stationary phase | [16,22,90–92,149] |
| Rv2031c | hspX | Heat shock protein | Proposed role in the maintenance of long-term viability or replication during latent or initial infections, respectively | Low oxygen, nutrient starvation, macrophage infection, stationary phase | [16,22,90–92,149] |
| Rv0251c | acr2 | Heat Shock protein | Involved in the initial step of translation at high temperature | High temperature, nutrient starvation | [16,97,98,100] |
| Rv0353 | hspR | Probable heat shock protein transcriptional repressor | Involved in the transcriptional repression of heat shock protein | High temperature | [100] |
| Rv2623 | usp | Universal stress protein family protein TB31.7 | Function unknown | Low oxygen, nitric oxide, macrophage infection | [21,103–107] |
| **Regulatory proteins** | | | | | |
| Rv3416 | whiB3 | Transcriptional regulatory protein WhiB-like WhiB3 | Involved in transcriptional mechanisms | Low pH, nutrient starvation, phosphate starvation | [108,109,171] |
| Rv3133c | dosR | Two component transcriptional regulatory protein | Regulatory part of two component system | Low oxygen, nutrient starvation, nitric oxide | [16,22,103,112,117–119] |
| Rv3583c | carD | Transcriptional regulatory protein | Regulation of rRNA transcription | DNA damage and nutrient starvation | [57] |
| **Information pathways** | | | | | |
| Rv1221 | sigE | Alternative RNA polymerase sigma factor | Promotes the attachment of RNA polymerase to transcriptional initiation site | Nutrient starvation, macrophage infections, high temperature, low pH, detergent stress | [16,99,100,122,124–126,132] |
| Rv3223c | sigH | Alternative RNA polymerase sigma factor | Regulation of thioredoxin cycling in oxidative stress response | Macrophage infections, high temperature, low oxygen | [100,132,234] |
| **Lipid metabolism** | | | | | |
| Rv0470c | pcoA | Cyclopropane synthase | Involved in the synthesis and modifications of mycolic acid | Low temperature | [140,235] |
| Rv3130c | tgs1 | Triacylglycerol synthase 1 | Involved in the synthesis of triacylglycerol | Low oxygen, low pH, low nutrient, high CO₂ | [143,144] |
| Rv3546 | fadA5 | Acetoacetyl-CoA thiolase | Involved in β-oxidations of side chains of cholesterol | Cholesterol, human macrophages | [147,149] |
| Rv3526 | kshA | Oxygenase component of 3-ketosteroid 9α-hydroxylase | Involved in cholesterol catabolism | Nutrient starvation | [16,152] |
| Rv3571 | kshB | Reductase component of 3-ketosteroid 9α-hydroxylase | Involved in cholesterol catabolism | Microaerophilic conditions, nitrosative stress | [152,236] |
| Rv3568c | hsaC | Extradiol dioxygenase | Involved in cholesterol catabolism | - | [153] |

(Continued)
survival of mice relative to the wild type infected, suggesting the role of trehalose remodeling in the persistence of M. tb [45]. Probably, the need of TreS protein for persistence could be due to the increased need of trehalose or perhaps to catalyze the stored depot of trehalose to maltose followed by conversion to readily usable glucose [45]. Recent studies have shown that non-replicating M. tb uses trehalose as an adaptive strategy during hypoxic conditions by remodeling of trehalose metabolism and decreasing the synthesis of glycolipids such as trehalose monomycolate (TMM)/TDM [50–52]. Further Lee et al. (2019) states that drug-induced persistence includes remodeling of trehalose metabolism to increase the carbon flux toward the synthesis of glycolytic intermediates as well as pentose phosphate pathway intermediates that are the source of alternative biosynthetic energy molecules like ATP and NADPH along with antioxidants all for the survival of the bacilli during persistence [53].

### Table 2. (Continued)

| Rv no. | Gene name | Functional product | Function | Induction conditions | References |
|--------|-----------|--------------------|----------|----------------------|------------|
| Rv0955 | perM      | Probable conserved integral membrane protein | Probably involved in cell division | Magnesium limitation, low pH | [155,160] |
| Rv3671c| mapP      | Membrane associated serine protease | Hydrolysis of peptides/ proteins at serine residue | Low pH, oxidative stress | [160,237] |
| Rv1477 | ripA      | Peptidoglycan hydrolase Amidase | Involved in hydrolysis of peptidoglycan | Low pH | [164] |
| Rv3717 | ami1      | Peptidoglycan hydrolase | Involved in hydrolysis of peptidoglycan peptide stems | - | [164] |
| Rv0930 | pstA1     | Phosphate transport system permease protein | Involved in active transport of inorganic phosphate and substrate across the membrane | Nutrient starvation | [170] |
| Rv3301c| phoY1     | Phosphate transport system transcriptional regulatory protein | Transcriptional regulation of inorganic phosphate | Nutrient starvation | [169,170] |
| Rv0821c| phoY2     | Phosphate transport system transcriptional regulatory protein | Transcriptional regulation of inorganic phosphate | Nutrient starvation | [169,170] |

*ald*

ald is one of the genes that encode alanine dehydrogenase and is induced under hypoxic conditions [54]. Ald is a multispecific enzyme that has two enzymatic activities, one is pyruvate reductive aminase activity, which catalyzes pyruvate to alanine and vice versa. The other activity is glyoxylate reductive aminase, which catalyzes the conversion of glycine to glyoxylate. Both enzymatic activities are coupled to oxidation of NADH thus forming NAD [54]. During hypoxic conditions, M. tb switches its energy sources from carbohydrates to fatty acids, and the glyoxylate cycle works as an anaplerotic reaction to synthesize four-carbon compounds as the substrate for β-oxidation of fatty acids [34]. There is no change in the survival of ald mutant under hypoxic conditions but there is a significant delay in the recovery of persistent bacteria upon reaeration, which is due to the altered NADH/NAD ratio [55]. It is also necessary to maintain the redox balance of persistent bacteria by regulating the NADH/NAD ratio. During reactivation, this NADH/NAD ratio acts as a signal for the conversion of the non-replicating persistent state of bacteria to active growth and an optimal NADH/NAD ratio may be required for this transition, and if this ratio is not achieved, it may remain in a non-replicating persistent state.

*relA*

The stringent response is an adaptive strategy of mycobacteria to cope with numerous stress conditions such as nutrient starvation [56–58], oxidative stress [57], and stationary phase [58]. This stringent response is characterized by the accumulation of hyperphosphorylated guanine nucleotides like (p)ppGpp controlled by RelA. RelA is a bifunctional protein consisting of two enzymatic activities (p)ppGpp synthetase catalyzes the transfer of pyrophosphate from ATP to GDP and GTP led to the synthesis of ppGpp and pppGpp, respectively [56]. RelA has (p)ppGpp hydrolase activity that results in dissociation of pyrophosphate group from it to give GTP or GDP as by-products [59]. Inactivation of relA gene in M. tb causes failure of the pathogen for prolonged survival under *in vitro* culture conditions [56] and also hampers its ability to persist in the chronic infection phase of mouse model, suggestive
of the importance held by RelA for persistence in the chronic phase of *M. tb* infection [60,61]. Previous studies reported microarray analysis of *relA* mutants under nutrient sufficient or deficient conditionsthat resulted in the increased expression of several transcripts, indicating their involvement of multiple cellular processes in the persistence of tuberculosis infection such as heat shock proteins, PE/PGRS family members, cell wall synthesis enzymes, transcriptional factors, and virulence factors [60], but the one specifically involved in persistence is not yet known. Insights into the role of RelA protein concerning mycobacterial persistence have to be gained and the individual enzymatic activity of this enzyme needs to be studied in-depth. The (p)ppGpp synthetase activity of RelA enzyme was abolished by point mutations in *M. tb*, which led to impaired growth and biofilm formation *in vitro* and abrogates *M. tb* to persist in the chronic phase of mouse infection [62]. However, the hydrolase activity of RelA enzyme is required both in the acute and chronic phases of infection indicative of the role of RelA in maintaining optimal levels of (p)ppGpp, which itself controls numerous cellular processes like GTP and ATP levels, DNA

### Table 3. Functional analysis of *M. tb* persistence genes through mutational, deletion, and overexpression studies.

| Gene | Information from mutational and expression studies | References |
|------|----------------------------------------------------|------------|
| **Intermediary respiration and metabolism** | | |
| Rv0467 (icit1) | Mutant displays attenuated persistence in activated macrophages and during chronic phase of mice infection | [40] |
| Rv1211c (dglA) | Inactivation reduces glucan content and mutant is unable to persist in chronic mice infection | [44] |
| Rv3780c (fadD) | Mutant shows delayed recovery from the non-replicating persistence state | [55] |
| Rv2558c (relA) | Deletion reduces long-term survival *in vitro* and persistence in chronic mice infection | [56,60,61] |
| Rv2109c | Needed for persistence in chronic infection of mice | [66] |
| (prcA) | | |
| Rv2110c (prcB) | | |
| Rv0363c (fbe) | | |
| Rv1568 (bioA) | Necessary for establishment of persistence in mice | [78] |
| Rv2438c | Inactivation reduces the long term survival *in vitro* and non-replicating persistence is observed | [80] |
| (nadE) | | |
| Rv2702c (ppgk) | Double mutant has impaired persistence as demonstrated in chronically infected mice | [87] |
| Rv0650 (gka) | | |
| Rv1620c (cydC) | Gene mutation enhances the killing of *M. tb* in isoniazid treated chronically infected mice | [88,89] |
| **Virulence, detoxification and adaptation** | | |
| Rv0126c (trcS) | Deletion mutant shows increased rate of mice survival | [45] |
| Rv2031c (hspX) | Deletion mutant shows increased bacterial growth upon tuberculosis infection in mice as well as in resting and activated macrophages *in vitro* | [90–92] |
| Rv0251c | Increased expression rapidly after entering the host cell during hypoxia and macrophage infection | [97,98] |
| (acr2) | | |
| Rv0353c (hsp90) | Inactivation reduces the persistence ability | [100] |
| Rv2623c (uap) | Deletion increases the bacterial growth and fails to establish a chronic tuberculosis infections in animals | [107] |
| **Regulatory proteins** | | |
| Rv3416c (whiB3) | Mutant shows attenuated persistence in macrophages and guinea pigs model of infection | [109] |
| Rv3133c | Inactivation reduces the *M. tb* persistence in mice, guinea pigs, white rabbits and rhesus macaques | [117–119] |
| (dosA) | | |
| Rv3583c (canD) | Deletion reduces the bacterial survival in acute and chronic infection of mice | [57] |
| **Information pathways** | | |
| Rv1221c (sigE) | Deletion mutant had reduced persistence in macrophages and in chronically infected mice | [99,124–126] |
| Rv3323c (sigH) | Deletion mutant causes increased apoptosis in non-human primate model | [234] |
| **Lipid metabolism** | | |
| Rv0470c (gcaA) | Inactivation reduces the persistence in mice | [146] |
| Rv3133c (tpsG) | Mutant decreases accumulation of TAG as well as antibiotic tolerance | [143,144] |
| (tpsF) | | |
| Rv3546c (fadA5) | Attenuated phenotype in chronic phase of *M. tb* infection due to disruption of cholesterol catabolism | [147] |
| Rv3526c (kshA) | Mutants are unable to persist in acute and chronic phase of mice infection | [152] |
| Rv3371c (kshB) | | |
| mce4 | Required to persist in IFN-y activated macrophages and in lungs of chronically infected mice | [82] |
| Rv3568c (lsaC) | Mutants unable to persist in lungs of guinea pig | [153] |
| **Cell wall and cell processes** | | |
| Rv0955c (pem) | Required for persistence in chronically infected mice | [155] |
| Rv3571c | Deletion lowers the persistence ability in the chronic phase of mice infection | [160] |
| (marP) | | |
| Rv1477c (ripA) | Mutant shows attenuated persistence in chronic phase of mice infection | [164] |
| Rv3717c (amiI) | Required for persistence in chronic phase of mice infection | [164] |
| Rv0930c | Inactivation decreases the persistence in mice | [170] |
| (pamA) | | |
| Rv3301c (phoY1) | Disruption decreases the persistence in chronically infected mice | [169,170] |
| Rv0821c | | |
| (phoY2) | | |
replication, translation machinery, and metabolism [62].

**prcA and prcB**
The *M. tb* prcA and prcB genes encode for the α-subunits and β-subunits of 20S proteasome respectively. It is anticipated that PrcBA is needed for the optimal in *vitro* growth of *M. tb* [63]. *M. tb* mutants lacking the proteasome accessory factors genes, such as *map* or *pafA* genes have low virulence, reflecting proteasome significance in the pathogenesis of *M. tb* [64,65]. The core of proteasome here plays crucial roles in defense against reactive nitrogen intermediates stress and also in the persistence of *M. tb* for chronic infections, as confirmed through genetic silencing of prcBA [66]. Thus prcBA is dispensable for the growth of *M. tb*. Although, when prcBA mutant was complemented by the active and mutated proteolytic proteasome, it states that proteasomal proteolytic activity is neither required for nitric oxide defense and nor for in *vivo* and in *vitro* growth of *M. tb* [67]. Conversely, proteasomal proteolytic activity is indispensable for the long-term survival of *M. tb in vitro* and chronic phase of mice infection. Further studies indicate that nitric oxide is not culpable for the attenuation of *M. tb* prcBA mutant in the chronic phase of infection, but some other mechanisms that control the mycobacterial persistence facilitated by proteasomal proteolysis. Intriguingly, *M. tb*, which lacks prcB was unable to survive in *vitro* under nutrient starvation and stationary phase conditions and was failed to persist in *vivo* under the same conditions [67]. Previous studies in *E. coli* indicates that under nutrient starvation conditions there is an adaptation strategy for the survival of bacteria by increasing the degradation of ribosomal proteins through Lon protease, which has led to the availability of amino acids for the synthesis of new enzymes that regulate the essential cellular processes [68]. Likewise, *M. tb* proteasome core genes may be crucial to maintaining long-term persistence in the host by regulating the turnover of proteins and amino acid supply.

**fba**
It encodes the class II fructose-1,6-bisphosphate aldolase (FBA), which reversibly catalyses the cleavage of fructose-1,6-bisphosphate to produce glyceraldehyde-3-phosphate and dihydroxyacetone phosphate in the glycolysis cycle. *M. tb*, both replicating and persistent, expresses this enzyme in *vitro* under stressful conditions like low oxygen tension, stationary phase, and change of carbon sources and is needed for glycolysis and gluconeogenesis [69]. It was found to be induced under *in vivo* tuberculosis infections in mice and guinea pigs. Furthermore, persistent *M. tb* bacilli have increased *fba* gene expression under low oxygen tension conditions as an adaptation strategy [70]. Depletion of *fba* gene in *M. tb* led to strong attenuations in the ability to reside in the mouse lungs and spleen while acute and chronic infections implying that this protein plays role in growth and persistence [71]. However, it is still unclear how this protein influences persistence mechanisms.

**bioA**
Biotin synthesis in *M. tb* starts with pimeloyl-CoA, a reaction that occurs through the actions of BioF, BioA, BioD, and BioB in four enzymatic steps [72]. It serves as an indispensable component required for the oxidation of carbon dioxide in acyl-CoA carboxylases and pyruvate carboxylase, both being a part of fatty acid metabolism and gluconeogenesis respectively [73,74]. Using S-adenosyl methionine (SAM) as an amino group donor, BioA catalyzes the second step of biotin synthesis by transamination of 7-keto-8-aminopelargonic acid (KAPA) to 7,8-diaminopelargonic acid (DAPA) [75–77]. In the absence of exogenous biotin, the bioA mutant fails to produce biotinylated proteins in *M. tb* that are essential for the fatty acid biogenesis, resulting in the elimination of mutant in biotin-free media. Conditional silencing of this mutant after the establishment of infection indicates that de novo synthesis of biotin is needed to sustain infection and persistence in a mouse model of TB infection [78]. As a result, the inactivation of BioA enzyme can be used as a target to clear off *M. tb* during both the acute and chronic phase of infection.

**nadE**
Nicotinamide adenine dinucleotide (NAD) biosynthesis is important since it regulates several processes including NAD cofactor pool, redox balance, respiration, central carbon, and energy metabolism. NAD biosynthesis is through the conversion of nicotinamide mononucleotide precursors to nicotinamide dinucleotide intermediates through two enzymes NaMN adenyltransferase (NaMD) and NAD synthetase (NaDE) [79]. Inactivation of *nadE* gene led to mutant *M. tb* with a substantial reduction in the ability for *in vitro* growth and non-replicative persistence, induced under nutrient limitations or low oxygen tensions and is subsequently eliminated in the acute and chronic phases of infection in mice [80]. Further, Rodionova et al. (2014) had used the protein knockdown approach to target NaMD and NaDE enzyme that resulted in the diminished of the NAD cofactor pool, which then prevents the metabolic flux in NAD(P)-dependent pathways including, central
carbon metabolism and energy production \[81\]. Taken together, these studies indicate that NadE is a potent persistence target whose inactivation leads to the loss of both the replicative as well as non-replicative persister bacilli.

**Ppgk and Glka**
The metabolic adaptations of *M. tb* are crucial for establishing and maintaining chronic infections in the host, and existing pieces of evidence suggest that fatty acids and lipids are the primary energy sources during infection \[82–86\]. Nevertheless, the significance of other carbon sources during infection and persistence is not known till date. PPGK (Polyphosphate glucokinase) and GLKA (Glucokinase) are the two functional glucokinases that metabolize glucose by conversion of glucose to glucose-6-phosphate. Deletion of *ppgk* gene led to a mutant with mild attenuations while growing in the presence of glucose and this indicates that the mutant possesses the ability to use glucose as an energy source during infection \[87\]. However, in absence of both glucokinases, PPGK and GLKA, the *M. tb* mutant is impaired to persist in the mice chronic infection model, thus implying that the *M. tb* relies on the phosphorylation of glucose to access glucose as an energy source to survive under the chronic infection \[87\].

**cydC**
The *cydC* encodes an ATP-binding protein ABC transporter that is necessary for the assembly of cytochrome bd oxidase and is upregulated in presence of hypoxia and nitric oxide in vitro and during the chronic phase of mice infection \[88\]. Deletion of *cydC* had attenuated the *M. tb* growth and survival during its transition to the chronic phase of mice infection as well as increases the clearance of *M. tb* in chronically infected mice treated with isoniazid, relative to wild type \[88,89\]. Further, this might be possible that isoniazid activation by catalase releases nitric oxide and inhibits cytochrome bd oxidase activity, enhancing isoniazid-mediated *M. tb* killing \[89\]. But how *cydC* gene affects the mycobacterial persistence and the enhanced killing of *M. tb cydC* mutant by isoniazid in chronically infected mice is not yet clear.

**Virulence, detoxification, and adaptation**

**hspX andacr2**

HspX and Acr2 proteins belong to the alpha crystalline-like protein family. Under hypoxic conditions, the transcript levels of *hspX* or *acr* (Rv2031) gene increases in *M. tb*, which indicates that this protein is required for adaptation to the hypoxic conditions within the host \[90\]. Deletion of *hspX* gene increased the growth rate of mutant in comparison to the wild type *M. tb*, in the macrophages and in mice infection. This suggests that it is required for the active growth and transitioning from the log to stationary phase in bacteria \[90–92\]. Under the stationary phase of bacteria, this protein was assumed to stabilize the *M. tb* cell wall by its chaperonin activity, which influences bacterial growth rate directly or indirectly \[93\]. This protein is also immunodominant in humans indicative of its involvement in the mechanisms by which *M. tb* evades the immune response to establish infection, as evidenced by increased expression of it in the stationary phase \[94\]. Later, overexpression of HspX protein in Bacille Calmette–Guérin (BCG)-immunized mice (BCG:HSP) and the alone BCG-immunized mice, both kinds were protected to equal extent upon tuberculosis infection. But, in immunodeficient mice infected with BCG:HSP persist longer compared to control BCG strain, implying that HspX could be a potential vaccine candidate \[95\]. Further, HspX was used as a part of subunit vaccine adjuvanted with N, N’-dimethyl-N, N’-dioctadecyl ammonium bromide (DDA) and trehalose-6,6’-dimylcote (TDM) elicited a stronger humoral and T-cell mediated immune response, and could boost the BCG-primed immune response against *M. tb* infection in mice \[96\]. Another protein Acr2 (Rv0251c), a member of the alpha crystalline protein family, was induced in murine macrophages and in vitro under several stress conditions, including heat shock, high dose of nitric oxide, detergent stress, peroxide stress, and palmitic acid \[97\]. There is a strong induction of *acr2* gene expression shortly after the phagocytosis of *M. tb* by quiescent murine and human macrophages \[97,98\]. In addition, deletion of *acr2* gene had unaffected the *in vitro* growth of *M. tb* but persisted in IFN-γ activated human macrophages \[98\]. The *acr2* gene expression is regulated through two proteins: SigE – controlled by heat shock and oxidative stress \[99\], and HspR – heat shock regulator \[100\]. Therefore, the early expression of this gene suggests that Acr2 appears to be an immunodominant antigen (Ag) that elicits a strong early immune response to *M. tb* infection \[98\].

**hspR**

*hspR* is a gene that exists in an operon containing *hsp70, grpE*, and *dnaJ* genes. These heat shock proteins are found to have functional interactions with Hsp70 \[101\]. It acts as a repressor that controls the expression of *hsp70* operon and *clpB* gene of *M. tb* \[100,102\]. Deletion of *hspR* gene in *M. tb* led to the reduction in the survival of this mutant in bone marrow-derived macrophages and
chronically infected mice model that suggests metabolic adaptation in the hspR mutant that could be beneficial for mycobacteria survival in acidified phagosome during the chronic phase of infection [100]. Overexpression of Hsp70 protein combined with inactivation of hspR mutant leads to an increased Ag expression per bacteria that might generate a stronger immune response and adopt this mutant as an attractive target to strengthen the host immune responses during persistent infection of M. tb [100].

**usp**

Rv2623 is a universal stress protein of M. tb and a member of the dormancy regulon, which has increased expression under low oxygen tension and high nitric oxide [21,103,104]. It is also highly induced in mouse and human macrophages along with its increased expression in the lungs of chronically infected mice [105,106]. Furthermore, deletion of Rv2623 gene in M. tb shows hypervirulent phenotype, as evidenced by increased mortality, histopathology, and bacterial development. Besides, *in vitro* overexpression of Rv2623 in M. tb results in bacterial growth retardation as compared to the parental strain. Together, this information suggests that Rv2623 is essential for the establishment of persistent infection by regulating the M. tb growth under *in vitro* and *in vivo* conditions [107]. More importantly, point mutations in the ATP binding site of Rv2623 exhibit normal bacterial growth as parental strain, implying that Rv2623 regulates the mycobacteria growth in an ATP-dependent manner [107]. Nevertheless, the accurate mechanism by which it is involved in persistence is still unknown.

**Regulatory proteins**

**whiB3**

WhiB3 is a redox-sensitive transcriptional regulator with four iron-sulfur (Fe-S) cluster that responds to host generated oxygen and nitric oxide to maintain the redox homeostasis [108]. In addition, it encourages the growth of persistent bacilli under different stress conditions such as low pH and nutrient starvation [108,109]. In previous studies, it was reported that deletion of *whiB3* M. tb and *Mycobacterium bovis* (*M. bovis*) had little effect on the growth of two animal models, mice and guinea pigs, though there was a reduction in colony-forming counts (CFU) of *M. bovis* WhiB3 mutants in guinea pigs model of infection [110]. In contrast, a recent study has shown that *whiB3* mutant of M. tb causes *in vivo* attenuation in the lungs of guinea pigs and has an impaired ability to survive in macrophage [109]. However, the mechanisms by which *M. tb* senses the different stresses and modulates the host immune system to promote bacterial persistence are not well understood. Transcriptomic analysis reveals that the functioning of *whiB3* gene facilitates M. tb adaptation in infected macrophage by controlling the expression of virulence, lipid production, redox homeostasis, cell wall remodeling and metabolic adaptation in response to available carbon sources whereas host microarray indicates WhiB3 protein of M. tb regulates the expression of host cell cycle genes and DNA damage checkpoints [111]. Conclusively, WhiB3 protein appears to be a redox sensor that controls polyketide expression by modulating bioenergetics metabolism in response to the host environment. During M. tb infection, activated macrophage releases polyketide and cyclomodulin, which arrests the host cell cycle and modulate the immune response, allowing long-term survival of persistent bacilli [111].

**dosR and dosS**

DosR (Dormancy survival regulator) comprises a regulon of more than 50 genes, that are activated in response to gradual depletion of oxygen and under nitric oxide stress inside granuloma, allowing the transition of active replicating M. tb bacteria to dormant state to cope up with these stresses and increase its long-term survival in the host [21,103,112,113]. Additionally, this regulon is crucial for the resuscitation of dormant M. tb bacilli to the active replicating state upon normoxic growth conditions [114]. The DosR regulon includes genes essential for persistence such as igs1 gene (triglyceride synthase), *hspx* (alpha crystalline family heat shock protein gene), and *Rv2623* (universal stress protein). The DosR regulon had been extensively studied, in M. tb, it is phosphorylated by two molecules DosS and DosT, under different growth-restricting conditions such as hypoxia, nitric oxide, ascorbic acid, and carbon monoxide [112,115]. The majority of research is diverted on dosR, as its expression is enhanced upon infection in macrophages, in various animal models, and during the latent stage of infection [112]. Inactivation of *dosR* in M. tb has previously shown no effect upon the bacterial burden and histopathology in different mice strains including, C57BL/6, DBA2, C3He/Fae, and C3HeB/Fae [20,116]. Whereas, other studies in C57BL/6 mice, guinea pigs, white rabbits, and rhesus macaques documented a strong attenuation in the growth of *dosR* M. tb mutant and impaired histopathology [117–119]. Overall, these findings demonstrate that DosR-regulated Ags delay the adaptive immune response during infection by inhibiting the T-cell response,
emphasizing the significance of DosR regulon in modulating the host immune response to facilitate the *M. tb* persistence [119]. However, the mechanism by which DosR adapts the *M. tb* in the hypoxic condition is unclear. Yang et al. (2018) substantiated that in hypoxic conditions, DosR is deacetylated, thus resulting in increased DNA binding ability, which eventually affects its regulon, allowing *M. tb* to rapidly adapt to hypoxic conditions and persist for longer periods [120]. In addition to DosR, DosS is also important for the persistence of *M. tb*. The dosS mutant of *M. tb* in macrophages is severely attenuated compared to the wild type *M. tb* and other dos mutants [121]. This is due to the induction of TNF-α and IFN-γ leading absence of phagosomal maturation arrest. The dosR mutant of *M. tb* is not attenuated within macrophages, indicating DosS can perform functions independent of DosR [121]. Supporting the above findings, the dosS mutant of *M. tb* was severely attenuated in C3HeB/FeJ mice and rhesus macaques but could grow under microaerophilic and hypoxic conditions, suggesting that the attenuation was not due to hypoxia [121]. Recent evidence suggests that 36 out of 51 dos genes are upregulated in presence of cholesterol as a carbon source both in actively replicating *M. tb* as well as in hypoxic conditions [113]. Furthermore, the induction of tgs-1 gene is inhibited relative to other dos genes in response to prpR deletion using cholesterol in the growth medium, suggesting that PrpR rather than DosR regulates TAG synthesis utilizing cholesterol as a carbon source [113].

carD
CarD is a transcriptional regulator protein that regulates the transcription of rRNA genes in mycobacteria by binding to the β-subunit of RNA polymerase [57]. It is induced in presence of stress conditions such as oxidative stress, DNA damage, and nutrient deprivation. Further, deletion of the carD gene in *M. tb* causes bacterial survival to be attenuated in both the acute and chronic phases of mouse infection, indicating the CarD is required not only in bacterial replication but also requisite for *M. tb* persistence [57].

**Information pathways**

**sigE**
Extra cytoplasmic RNA polymerase sigma factor (SigE), one of the best-studied sigma factors in *M. tb*, is encoded by the sigE gene. It acts as a central regulator of *M. tb* stress response that induces under a variety of stressful environments including pH stress, heat shock response, oxidative stress, detergent stress, vancomycin mediated cell surface stress, and during growth in human macrophages [122]. Deletion of sigE gene in *M. tb* triggered its persistence in the lungs of *M. tb* aerosol-infected mice due to delay in death time of this mutant [123]. Since the sigE mutant was unable to block phagosome maturation in macrophages, inactivation of sigE gene led to the decreased viability of this mutant in both naïve and activated macrophages [99,124]. This mutant was strongly attenuated, indicating that it was unable to grow in mice and generate a heightened immune response than wild type *M. tb* [125,126]. Under low phosphate concentrations and chemical stress during infection, the sigE mutant is needed for the synthesis of *M. tb* capsular polysaccharides [127]. Additionally, the microarray analysis of sigE mutant, indicating decreased transcript levels of classical heat shock proteins, transcriptional regulators, and enzymes involved in fatty acid oxidation [99]. Previous studies reported that it functions as a bistable switch that may be involved in persistor formation during hypoxic growth arrest [128,129]. However, it is unclear how important sigE deletion is for persistence during antibiotic treatment. To answer this problem, Pisu et al. (2017) reported that sigE mutant killed much faster than wildtype *M. tb* in presence of various antibiotics including vancomycin, gentamicin, rifampin, streptomycin, isoniazid, and ethambutol, which revealed that fewer persisters remaining in the sigE mutant culture [130].

**sigH**
SigH is an extracytoplasmic sigma factor of *M. tb* that is induced under different stress conditions such as oxidative stress, cell wall damage, phagocytosis, enduring hypoxia, heat shock response, and reaeration [131–133]. Possibly, it has a role in the reactivation of non-replicating persistent *M. tb* to actively growing *M. tb* [134]. Deletion of sigH gene in *M. tb* fails to induce granulomatous pathology despite *M. tb* replication in mice [135]. However, sigH gene mutant of *M. tb* in the non-human primate (NHP) model induces highly organized human-like granulomatous lesions and generates a heightened immune response to the bacilli upon infecting the host macrophages as compared to the wild type *M. tb* [136]. This heightened immune response was manifested by the increased level of β-chemokine secretion and chemotaxis of inactivated monocytes and increasing the extent of apoptosis. Thus, SigH appears to be crucial for modulating the host immune response during *M. tb* infection by secreting molecules that interact with the host immune machinery and modulate chemotaxis and apoptosis. Ultimately, it would significantly promote the long-term survival of *M. tb* that facilitates the persistence and spreading of initial
infection because chemotaxis is required for the migration of activated immune cells to the site of infection and apoptosis is an innate mechanism that is required for the clearance of *M. tb* [137,138]. To strengthen this point, a study by, Du et al. (2016) reported that inactivation of SigE and SigH transcription factors in *M. tb* leads to impaired ability to recover from persistence [139].

**Lipid metabolism**

*pcaA*

*pcaA* gene encodes cyclopropane synthase that has methyltransferase activity, one of the enzymes involved in the modification of mycolic acid present in the cell wall of mycobacteria. This enzyme is essential in the cord formation and synthesis of the proximal cyclopropane ring of alpha mycolic acid in *M. tb* and BCG [140]. Deletion of *pcaA* gene led to the impaired cyclopropanation, altered colony morphology, and inability to form serpentine cords that result in enhanced replication in the initial phase of infection as compared to wild type *M. tb* and inability to persist in the chronically infected mice. Ultimately, this suggests the significance of PcaA protein in the development of persistent chronic infection [140]. Now, the question comes in mind as to how *pcaA* gene expression influences *M. tb* persistence. Sequentially, autophosphorylation of serine/threonine-protein kinase (STPK) by some host signal in phagosomes led to the phosphorylation of PcaA at two residues, threonine-168 and threonine-183 that results to the several outcomes, including it inhibits the formation of cyclopropane rings in the cell wall of *M. tb*, as shown by the lack of di-cyclopropanated alpha mycolic acid, restricts intramacrophage replication, and prevents phagosome-lysosome fusion [141]. Consequently, it was discovered that PcaA is needed for the survival of mycobacteria during persistent chronic infection because it regulates the fusion of late endosomes to lysosomes.

*tgs1*

The family of triacylglycerol synthase contains 15 genes, one of which, *tgs1* gene, is responsible for the accumulation of triacylglycerol (TAG) in *M. tb* under various stress conditions [142,143]. As *M. tb* is exposed to several stress conditions such as hypoxia, nitric oxide, acidic pH, and low nutrient, TAG accumulates as an energy reserve in the dormant state of *M. tb*, allowing it to persist for long periods [142,144]. Interestingly enough, a recent study has proved that *M. tb* exploits the host TAG by releasing fatty acid that accumulates in the form of TAG in *M. tb* during infection [145]. In contrast to wild type, a mutant of *tgs1* gene in *M. tb* abolishes TAG accumulation and unable to tolerate antibiotics under stress conditions [143,144].

**mce4**

Cholesterol is also a lipid-based carbon and energy source in addition to fatty acids utilized by *M. tb* for growth under nutrient deprived conditions within macrophages during infection, as reported by several studies [146]. Though genome of *M. tb* lacks the genes for cholesterol synthesis, however the genes needed for scavenging the host cholesterol such as for its transport and catabolism are present [82]. Mce4 (Mammalian cell entry protein) is one of the well-studied cholesterol import system of *M. tb*, required for the acquisition of host cholesterol. This transporter system is reported to be dispensable for growth, both in resting macrophages and during establishment of mice infection. However, needed for *M. tb* growth in IFN-γ-activated macrophages, wherein it persists for longer periods in lungs of chronically infected animals [82].

**fadA5**

*fadA5* (Rv3546) encodes β-ketoacyl-CoA thiolase that carries the β-oxidations of side chains of cholesterol. *fadA5* synthesis is regulated by cholesterol and KstR protein such that the former upregulates and the latter represses its expression [147,148]. *fadA5* was found to be upregulated in the *in vitro* cultures of *M. tb* supplemented with cholesterol along with human macrophages [149] and mice lungs [150] infected with *M. tb*. This observation indicates the involvement of cholesterol during *in vivo* *M. tb* growth. FadA5 enzyme of *M. tb* catalyzes the conversion of cholesterol to androst-4-ene-3,17-dione (AD) and 1,4-androstanediene-3, 17-dione (ADD) by two successive β-oxidations [147]. These intermediate metabolites can be utilized by the *M. tb* as source of carbon and energy during *in vitro* and chronic phase of mouse lung infection that facilitates *M. tb* persistence. *fadA5* *M. tb* mutant has attenuated phenotype due to the disruption of the cholesterol metabolism that is requisite for the persistent phase of *M. tb* infection [147,148].

**kshA and kshB**

*kshA* and *kshB* genes of the *M. tb* cholesterol catabolic pathway encode for 3-ketosteroid 9α-hydroxylase (KSH) enzyme, which is required for opening of sterol ring of cholesterol [151]. It catalyzes the conversion of ADD to 9-hydroxy-1,4-androstanediene-3, 17-dione steroid intermediate for the utilization of cholesterol by *M. tb* during infection. Deletion of these two genes in
M. tb impairs the ability of bacteria to persist for longer periods in the stationary growth phase under the microaerophilic conditions [152]. Thus, these are indispensable for the growth as well as persistence in both the resting and activated macrophages. kshA and kshB mutants are unable to grow and persist in acute as well as chronic phase of murine infection [152]. These attenuated mutants cannot metabolize cholesterol and 4-androstadiene-3, 17-dione intermediates as carbon and energy source during infection [152].

**hsaC**

hsaC gene encodes an iron-dependent extradiol dioxygenase (HsaC) that catalyzes the final step of cholesterol degradation in M. tb. HsaC catalyzes the extradiol ring cleavage of DSHA (3,4-dihydroxy-9,10-seco-nandrost-1,3,5(10)-triene-9,17-dione) to produce 4,9-DSHA (4,5–9,10-disco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic acid) [153]. Studies carried with immunocompromised mice infected with either hsaC deletion mutant of M. tb or the parental strain reveals prolonged survival of the former. Likewise, in guinea pigs hsaC mutant of M. tb shows less granulomatous lesions, spreads relatively slow in the spleen and is unable to persist within lungs [153]. This attenuated phenotype is owed to the disruption of cholesterol catabolism and the undesirable toxicity of catechols or quinones. Thus, M. tb uses cholesterol, whose catabolism begins at the initial stage of infection before the onset of the host adaptive immune response, which then becomes key nutrient at the chronic or later phase of M. tb infection [153,154].

**Cell wall and cell processes**

**perM**

PerM (rv0955) is an integral transmembrane protein, consists of ten transmembrane helix, and is indispensable for the persistence of M. tb. Initially, it has been shown that disruption of perM gene through transposon insertion directed to severe growth defects in the chronic phase of mouse infection but mild attenuation in the acute phase [155]. Therefore, the question arises what exactly is the role of PerM protein and how it regulates the mechanism of persistence in M. tb. Further research on this mutant, indicates that PerM is a component of the mycobacterial divisome complex that allows mycobacteria to divide by stabilizing FtsB. Remarkably, it maintains the level of FtsB, a conserved protein divisome that is essential for septum formation [156–158]. It is required in host mimicking stress conditions to maintain the level of FtsB that is crucial to control the cell division at the chronic phase of infection, but dispensable in the acute phase of infection [159].

**marP, ripA, and ami1**

The periplasmic serine protease MarP (Mycobacterium acid resistance protease) is present in M. tb. Under acidic conditions, marP mutant of M. tb was unable to survive because it failed to maintain intracellular neutral pH and gets severely attenuated to an extent that it shows impaired growth during the initial (acute) phase of infection and thus is unable to persist in the chronic phase of mouse infection [160]. Upon acid stress, the marP mutant bacteria forms elongated cells along with multiseptate chains indicative of their role in cell separation at low pH [161]. The mechanism by which MarP protein is required for the M. tb survival in acidic conditions found in the host phagosomes has been described. First, MarP senses acid stress and triggers inactive RipA cleavage, resulting in active RipA with peptidoglycan hydrolase activity [161]. Consequently, RipA regulates M. tb peptidoglycan hydrolysis a process required for cell wall homeostasis and bacterial cell separation and also important for M. tb survival in acidic environments. RipA and RipB (Resuscitation promoting factor interacting partners) are peptidoglycan endopeptidase that cleave the peptide bond between D-glutamic acid and diaminopimelate of peptidoglycan peptide stem [162]. Deletion of ripA in Mycobacterium smegmatis forms normal cells as they are in wild type M. smegmatis under regular growth conditions, but under acidic conditions, it results in elongated and multiseptal cells [161,163]. Nonetheless, in the case of M. tb, RipA is indispensable for cell division and cell growth during in vitro normal growth conditions as well as during persistent chronic phase of infection, but deletion of ripB gene did not affect cell division, though this enzyme is required in the absence of RipA [164]. It is needed not only for cell separation during cell division by peptidoglycan degradation at the septum but also enables incorporation of new peptidoglycan content during cell elongation by cleaving the peptidoglycan at the polar region [164]. This endopeptidase is found in the septa and poles region of M. bovis BCG [165] where it interacts with other cell wall enzymes including RpfB, a lytic transglycosylase [166] and PonA1, a peptidoglycan synthase [167]. In ripA mutant, it also affects the enzymatic activity of its interacting partner that might be helpful to control the peptidoglycan remodeling during the chronic phase of infection. RipA protein is necessary for the persistence of M. tb, but the precise mechanisms are unascertained. Intriguingly, a study by Shariq et al. (2021) demonstrates that RipA modulates the
metabolic reprogramming, as well as, inhibits autophagy and apoptosis of macrophages in conjunction with TLR-4 surface immune receptors [168]. Based on these facts, a significant survival strategy of M. \( tb \) involves employing RipA for replicating within macrophages, subdued the host immune defense. Another peptidoglycan-modifying enzyme, Ami1, which belongs to the L-alanine amidase family cleaves the peptide stem from the glycan’s backbone at N-acetylmuramic residue. While Ami1 is needed for mycobacterium persistence during chronic mouse infection, it is not required for cell division under \textit{in vitro} growth conditions. However, it is necessary for normal cell growth in \textit{M. smegmatis} [164]. The most probable reason for Ami1 importance in chronic phase infection is that it aids the cell division of a subpopulation that can withstand host-driven stress conditions.

\textit{pstA1, phoY1, and phoY2}

PhoY1 and PhoY2 are the two important proteins that play crucial roles in the formation of M. \( tb \) persister. Previous studies stated that phoY2 but not phoY1, is needed for \textit{in vitro} culture of M. \( tb \) and mouse model of tuberculosis infection [169], but a subsequent study found that both PhoY1 and PhoY2 are requisite for M. \( tb \) growth and survival in chronically infected mice [170]. However, the implication of PhoY proteins in M. \( tb \) persistence is unclear. To solve this puzzle, a recent study found that PhoY proteins function as a mediator between PstA1 phosphate transporter and SenX3-RegX3 two-component system to control the phosphate sensing signal transduction mechanism that somehow involved in persister formation. Under inorganic phosphate limiting and \textit{in vitro} growth conditions, deletion of the \textit{phoY1} and \textit{phoY2} genes, as well as the \textit{pstA1} gene, mediate the activation of RegX3, indicating a decrease in persister formation [170]. In addition, \textit{phoY} and \textit{pstA1} mutants in M. \( tb \) were more susceptible to rifampicin rather than isoniazid in aerosol-infected mice model of tuberculosis [170]. Furthermore, disrupting the \textit{regX3} gene increases the persister frequency under phosphate-limiting conditions [171–173]. As a result of these efforts, it appears that both PhoY and PstA1 proteins are required to inhibit the persister formation in M. \( tb \) by activating RegX3 under phosphate-limiting conditions or by disrupting the signaling between PstA1 and SenX3-RegX3.

\textbf{Impact of therapeutics on Mycobacterium persistence}

Current advancements in understanding molecular determinants involved in M. \( tb \) virulence and pathogenesis, as well as how bacteria evades the host immune defense and persist for long periods, can provide detailed information about the dynamic relationship of human host and pathogen. With this information, researchers may be able to develop new therapeutics that target different stages of tuberculosis pathogenesis, such as the active and latent stages of infection, to completely eradicate the bacteria and improve defense against transmission. Table 4 lists various therapeutic regimens for active and latent tuberculosis detection.

\textbf{Diagnoses}

It is a strenuous task to diagnose the non-replicating bacilli as there is no suitable diagnostic test to do so; hence it is not possible to assess the level of persistence in tuberculosis-infected asymptomatic individuals. Since latent tuberculosis infection (LTBI) is linked with low tissue bacterial burden, any diagnostic scheme based on identifying the bacteria or its biological components is more challenging. The cellular immune response resulting from mycobacterial Ags, LTBI are usually diagnosed rather indirectly. LTBI is diagnosed most often by blood-based IGRA (Interferon gamma release assay) and skin-based TST (tuberculin skin test). TST evaluates delayed-type hypersensitivity against purified protein derivatives (PPD) of mycobacterial cells \textit{in vivo}, with the outcome being the extent of the skin induration region over 2–3 days [174]. Tuberculin PPD is made of the protein precipitate of mycobacterial culture filtrates, that comprises of conserved chaperone proteins (constitutes nearly 60%) among mycobacterial species like heat shock proteins (HspX), 10-kDa chaperonin GroES, and 60-kDa chaperonin 1 (GroEL) [175]. However, the presence of conserved proteins in PPD impedes the TST to distinguish among various M. \( tb \) infections, for instance, environmental non-tuberculous mycobacteria, and BCG vaccination. In contrast, IGRA being a blood-based test identifies the IFN-\( \gamma \) release from the sensitized T-cells exposed to mycobacterial ESAT-6 and CFP-10 \textit{in vitro} [174]. The IGRA test assesses the cell-mediated immune response, wherein the outcome depends upon the IFN-\( \gamma \) levels generated from the circulating effector memory cells [176] and the effector T cell frequency. As a result, neither BCG vaccination nor exposure to non-tuberculous mycobacteria affects IGRA results. However, the individuals with high incidence of M. \( tb \) exposure like healthcare professionals are shown to give variable IGRA result values. This implies that either there is poor test repeatability or reinfection-inducing reversion as a consequence of ongoing exposure to
mycobacterial Ags [177]. Furthermore, in low-risk populations, erroneous conversions seem to be more frequent with IGRA’s than with TST [178]. Improving on existing TST and IGRA to generate better tests is one way for addressing this issue. The C-Tb hypersensitive skin test sensitive to recombinant ESAT-6 and CFP-10 proteins is an example of this approach [179]. The high specificity of IGRA and the minimal cost of TST are meant to be combined in this diagnostic test. Additionally, two more commercially available diagnostic tests, namely Quantiferon (QFT) and QFT TB Gold in tubes (QFT-GIT), are composed of long peptide derivatives of ESAT-6 and CFP-10 Ags. Another diagnostic test called as QFT-TB Gold Plus (QFT-Plus), is developed that contains both long peptides derived from ESAT-6 and CFP-10 Ags to elicit specific CD4+ T-cell response and short peptides for IFN-γ release by CD4+ and CD8+ T-cells [180]. It is observed that addition of peptides to stimulate CD8+ T-cells can assist to distinguish LTBI from active TB [181,182]. In people with LTBI, the QFT-Plus assay has a greater correlation with increased M. tb exposure than the QFT-GIT assay [180]. T-SPOT.TB is another diagnostic test that is based on ESAT-6 and CFP-10 Ags of M. tb. The ELISPOT technique used in this assay quantifies the level of IFN-γ produced by the T-cells, which necessitates an expensive reader machine, appropriate software, and specialized trained staff, thus limiting its applicability in developing countries [183]. According to studies, the metabolism of M. tb keeps changing during infection, which is reflected by the variable expression of immunodominant Ags. This

Table 4. Numerous potential drug and vaccine candidates for M. tb that have been developed recently with their respective stages of clinical trials are listed.

| Latent TB drug | Formulation of therapeutic regimens | Clinical trials |
|----------------|--------------------------------------|----------------|
| DOLPHIN       | Isoniazid and rifampicin             | Phase I/II     |
| IMPAACT4TB    | Isoniazid and rifampicin             | Phase I/II     |
| IMPAACT P2001 | Isoniazid and rifampicin             | Phase I/II     |
| TBTC Study 3/5| Isoniazid and rifampicin             | Phase III      |
| AS279/BRIEF TB| Isoniazid and rifampicin             | Phase III      |
| AS300B/I2003/ | Delamanid                            | Phase III      |
| PHOENix       | Isoniazid and rifampicin             | Phase II/III   |
| CORITIS       | Levofoxacin                          | Phase III      |
| TB-CHAMP      | Rifampicin                           | Phase II/III   |
| TBTC study 3/7| AERAS-402                             | Phase III      |
| ASTEMoid      | Vancomycin                           | Phase III      |
| V-QUIN trial  | Levofloxacin                         | Phase III      |
| WHIP3TB       | Isoniazid and rifampicin             | Phase III      |
| P1078 IMPAAT/ TB | A5300B/I2003/22                     | Phase III      |
| APPRISE       |                                     | Phase IV       |
| Vaccine       |                                      |                |
| Ad5Ag85A21    | Replication-deficient human adenovirus serotype-5 vector expressing Ag85A antigen of Mycobacterium tuberculosis | Phase I |
| H1-IC3122     | Recombinant fusion protein ESAT-6 and Ag85B of M. tb with IC31 adjuvant (TLR-9 agonist) | Phase I |
| H4-IC3122     | Recombinant fusion protein TB10.4 and Ag85B of M. tb with IC31 adjuvant (TLR-9 agonist) | Phase I |
| AEC/BC02122   | Ag85B antigen and Fusion protein of CFP-10 and ESAT-6 of M. tb with CpG adjuvant | Phase I |
| AERAS-42222   | Recombinant BCG vaccine expresses Ag85A, Ag85B, and Rv3407 antigens mixed with perfringolysin | Phase I |
| AERAS-40221   | Adenovirus serotype 35 (Ad35) expressing Ag85A, Ag85B, and TB10.4 antigens of M. tb | Phase I |
| ChAdOx185A – MVA85A21 | Replication-deficient chimpanzee adenovirus/ modified vaccinia Ankara virus vector expressing Ag85A antigen of M. tb | Phase I |
| GamTBVacc22   | Fusion of two M. tb proteins (Ag85A and ESAT6-CFP) with dextran-binding domain in DEAE dextran and CpG (TLR-9 agonist) adjuvant | Phase IIa |
| ID93/GLA-SE22 | Recombinant fusion protein (ID93) comprises four antigens involved in virulence (Rv2608, Rv2619, Rv2620) and latency (Rv1813) of M. tb with GLA-SE adjuvant (emulsion of glucopyranosyl lipid and MPL) | Phase IIa |
| MBBVCA23      | Attenuation via deletions of phoP and cadD26 genes in live strain of M. tb | Phase IIa |
| RUT2+22       | Liposome coated cell wall fragments of M. tb bacteria | Phase IIa |
| TB/FLU-04L21  | Attenuated influenza viral vector expressing Ag85A and ESAT-6 antigens of M. tb | Phase IIa |
| DAR-901 booster24 | Live attenuated Mycobacterium bovis | Phase IIb |
| M72/AS0122    | Heat killed whole cell or extract of Mycobacterium bovis | Phase IIb |
| H56/IC3122    | Recombinant M. tb fusion protein of three antigens expressed during initial (Ag85B), late (ESAT-6) and throughout the M. tb infection (Rv2660c) with IC31 adjuvant (a TLR-9 agonist) | Phase IIb |
| BCG Revaccination23 | Live M. bovis BCG vaccine | Phase IIb |
| VaccaeM204    | Whole cell or extract of Mycobacterium vaccae | Phase III |
| VPM100223     | Live recombinant M. bovis with urease C deletion and lysteriolysin insertion | Phase III |
| MIP/Immuvac14  | Heat killed Mycobacterium indicus pranii | Phase III |
allows to distinguish among different stages of infection and to assess the risk of active TB progression, for diagnostic purposes [184]. Numerous studies revealed that mycobacterial Ags Rv2628, Rv1737, Rv2092c, and Rv2004 elicit CD4+ and CD8+ T-cells and hence IFN-γ in LTBI individuals compared to those with active tuberculosis [174]. Likewise, a recent study categorized certain proteins under active and latent tuberculosis specific biomarkers. These include Alr, BfrA, EspR, TrpG, and TreY in active tuberculosis and HspR, NarG, PonA1 and PonA2 in latent tuberculosis [185–187]. Furthermore, assessment of these proteins would assist either in discovery of newer therapeutics or diagnostic markers to facilitate delineation between the active and latent stage of tuberculosis.

**Vaccine**

*M. tb* uses numerous tactics to hamper the host immune defenses. The persistence phenomenon empowers the bacteria to stay alive within the host in a latent state, in which infected individuals are asymptomatic and are unable to transmit the disease. Nevertheless, this latent or persistent stage bacterium is primarily responsible for the recalcitrance of chronic tuberculosis infection as when the bacteria encounter favorable conditions it resumes to form the wild type population of bacteria. It was verified in human studies that there is a gap in the expression of antigenic repertoire in individuals infected with active and latent tuberculosis [160,161]. Furthermore, most of the proteins involved in bacterial persistence were revealed through different omics approaches under various stress conditions imposed by the host have already been addressed in this review, could be used to design a vaccine against the latent stage of tuberculosis [7]. To avert reactivation on latent tuberculosis individuals, these candidates should induce a T-cell response and neutralizing antibodies against the proteins involved in persistence. There are varied T-cell responses elicited to potential TB vaccines, as well as discrepancies in the relative strengths of immune responses, including the Th1, Th17, and CD8+ responses, both in humans and animal models [188]. Candidates for TB vaccines produce both CD8+ as well as CD4+ T-cell response having distinct characteristics, even though these responses have variations between studies in animals and clinical trials. BCG challenge induces multifunctional Th1 and Th17 responses in mice and nonhuman primates and partially protects against *M. tb* [189–191]. The intensity or multifunctional profiles of BCG-specific T-cells could not provide protection against pulmonary TB in the infants of South Africa [192]. Intriguingly, BCG-specific IFN-γ response is associated with a lower incidence of tuberculosis under the same circumstances [193]. Also, BCG-induced immunity and efficacy gradually fade, especially in high TB prevalence areas [194–196]. In comparison to BCG, the other live-attenuated mycobacterial vaccines like AERAS-422, VPM1002, and MTBVAC elicit stronger immune response, encompassing robust multifunctional CD8+ and CD4+ T-cell responses that enhance immunity in mice [197–200] but these responses are not substantially better from those elicited by BCG during clinical trials [201–204]. Although in infants the Ag-specific CD4+ T-cell responses evoked by MTBVAC were found to be stronger than those induced by BCG but, the CD8+ T-cell responses were low. Subunit vaccine candidates as BCG boosters stimulate Ag-specific CD4+ and CD8+ T-cell responses in mice leading to improved immunity. Nevertheless, noncoherent protection in NHPs (Ad5Ag85A, MVA85A, H1/H4/H56, and AERAS-402) [205–210] while modest immune responses in BCG-vaccinated infants (ID93, AERAS-402, M72, and MVA85A) [211–216] relative to adults were found for certain candidates. Based on clinical trials, MVA85A does not significantly enhance protection against *M. tb* infection regardless of heightened Th1 and Th17 responses [217,218], similarly, AERAS-402 triggers multifunctional CD8+ and CD4+ T-cells that are incapable of recognizing the *M. tb*-infected cells [219]. In contrast to BCG-induced responses, mycobacterial adjuvant subunit vaccine formulations preferentially stimulate co-expression of IL-2 cytokine and multifunctional CD4+ T-cell populations associated with increased protection in mice [220–222]. However, the relevance of these CD4+ T-cell populations in human protection remains undetermined. Also, the significance of variations in the immunogenicity of subunit vaccine antigenic components is yet to be determined [223,224]. As a therapeutic vaccine, MIP (*Mycobacterium indicus pranii*) shows promising results in animal models infected with *M. tb*, although in clinical studies, it shows obscure advantages in individuals infected with TB [225–227]. Though, there is a lack of correlates of protection for infants and adults from tuberculosis infection. The antigenic heterogeneity during an infection and the lack of host biomarkers are some of the factors that prevent tuberculosis vaccine trials from being successful. In conclusion, the development of a TB vaccine can be initiated through the use of relevant animal and human disease challenge models, synchronization between the outcomes of preclinical and clinical vaccine trials, as well as the assessment of vaccine candidates through advanced clinical trials.
Table 5. Inhibitors that target genes involved in M. tb persistence are enlisted with their respective inhibitory (IC\text{50}) concentrations.

| Inhibitors                                                                 | Target protein | Inhibition (IC\text{50}) | References |
|---------------------------------------------------------------------------|----------------|--------------------------|------------|
| 1-((4-methoxyphenyl)sulfonyl)-4',5'-dihydropiro[4,7'-thieno[2,3-c]pyran]   | Lat            | 1.04 ± 0.32 µM           | [229]      |
| N-(pyridine-2-yl methyl)-2-(4-(quinolin-4-yl) piperazin-1-yl) acetamide    | BioA           | 4.8 µM                   | [241]      |
| Biphenyl amide DG70                                                       | Fba            | 10 ± 1 µM                | [242]      |
| 2-Vinyl-o-tocitrate                                                       | 8-Hydroxyquinoline carboxylic acid | 0.0016 µM             | [243]      |
| 3-Nitropropionate                                                        | Compound 1     | 0.185 µM                 | [244]      |
| 3-Bromopyruvate                                                          | Compound 2     | 0.12 µM                  | [245]      |
| Itaconic acid                                                            | Compound 3     | 0.31 µM                  | [246]      |
| Methyl-4-(4-methoxyphenyl)-4-oxobut-2-enoate                             | Compound 4     | 0.013 µM                 | [247]      |
| Lead 1                                                                   | Compound 1'    | 0.17 µM                  | [248]      |
| Lead 2                                                                   | Compound 2'    | 153 nM                   | [249]      |
| Lead 3                                                                   | Compound A35   | 3.9 ± 1.2 mM             | [250]      |
| Lead 4                                                                   | Compound A36   | 88.16 µM                 | [251]      |
| Lead 5                                                                   | Compound A65   | 114.42 µM                | [252]      |
| Compound X9                                                               | Urea sulfonamide analog 4 f | 2.62 µM                  | [253]      |
| 8-Hydroxyquinoline carboxylic acid                                       | Phenylcoumarin derivative | < 26.2 µM             | [254]      |
| Compound 1                                                               | Artemisinin (HC101A) | 10 µM                    | [255]      |
| Compound 2                                                               | HC102A         | 10 µM                    | [256]      |
| Compound 3                                                               | HC103A         | 10 µM                    | [257]      |
| Compound 4                                                               | HC102A         | 1.9 µM                   | [258]      |
| Compound 5                                                               | HC103A         | 0.5 µM                   | [259]      |

Drug

The current drug regimen of tuberculosis is effective in killing drug-susceptible tuberculosis, but it is often ineffective in eradicating drug-resistant and drug-persistent tuberculosis infections. Persistent M. tb, which is non-replicating in nature, adapts in the host stress microenvironment through reducing metabolism and increasing phenotypic antibiotic tolerance [228]. Furthermore, under favorable growth conditions, persistent M. tb has the potential to convert into the active population of M. tb so it is critical to target the persistent state to prevent active TB progression. Till now, there is not even a single drug available on the market that explicitly targets the persistent mycobacteria. There lies an imperative requirement of potential drugs that can target both actively replicating as well as non-replicating characteristics of mycobacteria to fully wipe out the drug-resistant and persistent M. tb. The new potential drug candidate should possess the following characteristics: high safety with few side effects, shorter therapy length, oral bioavailability, and it should also target the persistent, multidrug-resistant, as well as extensively drug-resistant tuberculosis.

Recent research has discovered some effective inhibitors that target both active and dormant tuberculosis bacteria, as listed in Table 5, such as N-(pyridine-2-yl methyl)-2-(4-(quinolin-4-yl) piperazin-1-yl) acetamide, 1-((4-methoxyphenyl) sulfonyl)-4', 5'-dihydropiro [piperidine-4, 7'-thieno [2, 3-C] pyran] and biphenyl amide (DG70). The first two compounds inhibit the Lysine-ε aminotransferase enzyme that is responsible for reversibly catalyzed the transamination of lysine into α-ketoglutaric acid, while the third compound, DG70, act as a respiration inhibitor and inhibits the dimethyl menaquinone methyltransferase (MenG) enzyme that inhibits the final step of menaquinone synthesis [229–231]. Synergistic activity of these inhibitors, as well as existing drugs with established mechanisms of action could shorten treatment time and make highly effective against the treatment of tuberculosis.

However, many obstacles such as lack of suitable biomarker to measure its efficacy, inadequate information about the mechanism of persistence in mycobacteria, and lack of established animal models, slow down the drug-development process from the identification of lead compounds to the time until it is launched in
the market as an approved drug. Conclusively, the main goal of this review article is to explore more about the persistence mechanism in mycobacteria through its crucial molecular players involved in various essential processes, including lipid metabolism, intermediary respiration and metabolism, virulence, detoxification, adaptation, and cell wall synthesis.

Discussion and future remarks

The main reason for failures in treating clinical tuberculosis is the persistence of mycobacteria, which is transiently tolerant to drugs used in tuberculosis therapy. It provides a clear indication that conventional therapeutic options, such as the BCG vaccine and a combination of tuberculosis drugs, are insufficient to eradicate tuberculosis infection. In the past decade, the research on bacterial persistence have made significant progress. However, persistence remains to be a major issue to public health, so detailed investigation about the biology of persisters and their mechanisms is required to achieve better clinical results. Overall, there is an urgent need for the development of therapeutic options aimed at both active and latent M. tb bacteria. Although the development of some therapeutics, such as bedaquiline drug and M72-based vaccine had shown promising results, but the lag at the level of comprehensive understanding about the tuberculosis pathogenesis impedes the development of better therapeutics and diagnostics.

Research studies have found that multiple genes and regulatory pathways of both host and mycobacteria are responsible for persistence and their eventual relapse to actively-replicating wild type populations. The cohesive efforts of persister enrichment through approaches like fluorescence-activated single cell sorting and laser capture microdissection and analysis techniques such as time lapse microscopy, microfluidics technique, omics technologies, and next-generation sequencing, can provide robust information to understand the mechanism of persister formation and their reactivation. Gene network analysis and system biology techniques could assist to unravel the ways through which the molecular determinants of bacterial cells interact in stressful environments giving rise to numerous persister phenotypes, who even differ at their frequency level under different stress conditions.

Intriguingly, the in vitro model system that mimics the different stress conditions imposed by the host immune system on the pathogen provides a screening approach that recognizes the significance of M. tb genes in the adaptive response during infection. Various in vitro and ex-vivo models have been developed to imitate the stress conditions faced by the M. tb inside the host during infection. These models are established to understand the mycobacterial factors responsible for adaptation of bacteria to persistent state. But notable limitation of these stress models is that their information is not significant compared to the in vivo scenario in clinical and animal models. For instance, nutrient availability studies in the context of persistence in vitro differ considerably to those of in vivo conditions. As a matter of fact, different micro niches such as adipose tissues, macrophages, and mesenchymal stem cells of the human body are exploited by the mycobacterial cells to hide away from the host immune response. These hidden bacterial cells then utilize host fatty acids and cholesterol as carbon and energy sources to persist for long-term within the host. Thus, unraveling the relationship between the bacterial persistence and host metabolism can present newer avenues to develop therapeutics and diagnostics. The molecular determinants that are identified to be implicated in mycobacterium persistence are well described in this review, which gives certain insights into the biology of persister formation and its reactivation in mycobacteria. In addition, this information will also facilitate the development of biomarkers that could demarcate between active and latent tuberculosis to promote the molecular diagnosis of tuberculosis.

Another uncharted field of research includes the study of persistence in context of host microbiota, which is currently deemed interesting by many researchers. Although, bacterial persistence is assumed to be adverse as it is the reason for the recalcitrance of chronic infections, but persistence could be favorable for the survival as well as diversity of healthy microbes of host microbiome under conditions like pathogenic or viral infections, change in diet, age, and antibiotic treatment. Although, it is not substantiated that persister cell formation occurs in the host microbiome however, it is important to comprehend the possibilities of utilization of the persistence phenomenon to reestablish the host microbiota.

For M. tb a major obstacle to comprehend the mechanism of persister formation and subsequent relapse is the unavailability of clinical specimens and tissue samples from individuals with latent or persistent tuberculosis. In addition, there is a lack of imaging techniques and diagnostic tools to classify the persister cells in clinical specimens. Thus, due to the lack of thorough information about the persistent tuberculosis infection, creating clinically relevant
Persistence models is an arduous task. So, it is imperative to build well-designed specimen banks to preserve the clinical samples from individuals with latent or persistent tuberculosis, both prior or upon reactivation. This data is pivotal to develop therapeutic interventions for successful identification and targeting of the persistent or latent tuberculosis bacteria before it relapses in the host.

Notes

1. Prepared by mixture of Purecol collagen solution, Dulbecco’s phosphate buffer saline, fibronectin, and sodium hydroxide
2. Putative and known function
3. These genes are primarily presented based on induction conditions that have been associated with increase persistence in *Mycobacterium tuberculosis*.
4. Icl: Isocitrate lyase
5. Ald: Alanine dehydrogenase
6. Prc: Proteasome core
7. FBA: Fructose-1,6-bisphosphate aldolase
8. NAD: Nicotinamide adenine dinucleotide
9. PPGK: Polyphosphate glucokinase
10. GLKA: Glucokinase
11. Acr: Alpha crystalline
12. Usp: Universal stress protein
13. Dos: Dormancy survival
14. Tgs: Triacylglycerol synthase
15. TAG: Triacylglycerol
16. Mar: Mycobacterium acid resistance
17. Rip: Resuscitation-promoting factor interaction partner
18. Pst: Phosphate-specific transport
19. Sable SB, Posey JE, Scriba TJ. Tuberculosis vaccine development: progress in clinical evaluation. Clinical microbiology reviews. 30 October 2019;33(1):e00100-19.
20. https://www.who.int/publications/i/item/9789240013131
21. Recombinant live-attenuated or replication-deficient virus vector candidates
22. Mycobacterial fusion protein in an adjuvant formulation
23. Live-attenuated mycobacterial vaccine candidates
24. Mycobacterial killed, whole-cell, or extract vaccine candidates
25. IC₅₀: The concentration of chemical/drug/inhibitor required for 50% inhibition of a specific biological or biochemical function.

Author contributions

Hemant Joshi: Conceptualization, writing-original draft preparation, visualization, investigation Divya Kandari: Writing-reviewing and editing Rakesh Bhatnagar: Conceptualization, supervision.

Data availability statement

The authors confirm that the data support the findings of this study are available within the article.

Acknowledgments

The authors would like to show their appreciation to editor and reviewers for their constructive suggestions.

Disclosure statement

The authors declare no conflict of interest.

Funding

This work was financially supported by a grant to Hemant Joshi from Department of Biotecnology, Government of India [grant number DBT-JRF fellowship DBT/2017/JNU/849].

ORCID

Hemant Joshi http://orcid.org/0000-0002-6469-2814
Divya Kandari http://orcid.org/0000-0002-9575-0263
Rakesh Bhatnagar http://orcid.org/0000-0001-7184-6378

References

[1] Organization WH, *Global tuberculosis report 2020: executive summary*. 2020.
[2] Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with *Mycobacterium tuberculosis*: update 2010. Eur Respir J. 2011;37(3):690–711.
[3] Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60(6):699–709.
[4] Lebeaux D, Ghigo J-M, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510–543.
[5] Adams KN, Takaki K, Connolly L, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011;145(1):39–53.
[6] Manina G, Dhar N, McKinney JD. Stress and host immunity amplify *Mycobacterium tuberculosis* phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe. 2015;17(1):32–46.
[7] Joshi H, Verma A, Soni DK. Impact of microbial genomics approaches for novel antibiotic target. In *Microbial Genomics in Sustainable Agroecosystems* 2019 (pp. 75–88). Springer, Singapore.
[8] Arnoldini, Markus, Rafal Mostowy, Sebastian Bonhoeffer, et al. Evolution of stress response in the face of unreliable environmental signals. PLoS Comput Biol. 2012;8(8):e1002627.
[9] Wakamoto Y, Dhar N, Chait R, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science. 2013;339(6115):91–95.
[10] Balaban NQ, Gerdes K, Lewis K, et al. A problem of persistence: still more questions than answers? Nature Rev Microbiol. 2013;11(8):587–591.
[11] Dörre T, Vulić M, Lewis K. Ciprofloxacin causes persist-er formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 2010;8(2):e1000317.
[12] Zhang X, Song Z, He J. Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerg Microbes Infect. 2014;3(1):1–10.
[13] Gordhan BG, Peters J, Kana BD. Application of model systems to study adaptive responses of Mycobacterium tuberculosis during infection and disease. Adv Appl Microbiol. 2019;108:115–161.
[14] Loebel R, Shorr E, Richardson H. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol. 1933;26(2):167.
[15] Loebel R, Shorr E, Richardson H. The influence of foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol. 1933;26(2):139.
[16] Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002;43(3):717–731.
[17] Jamet S, Quentin Y, Coudray G, et al. Evolution of mycotic bioconversion genes and their regulation during starvation in Mycobacterium tuberculosis. J Bacteriol. 2015;197(24):3797–3811.
[18] Wayne LG, Hayes LG. An in vitro model for sequential study of growth/shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64(6):2062–2069.
[19] Voskuil M, Visconti K, Schoolnik G. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis. 2004;84(3–4):218–227.
[20] Rustad TR, Harrell MI, Liao R, et al. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One. 2008;3(1):e1502.
[21] Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol. 2003;48(3):833–843.
[22] Sherman DR, Voskuil M, Schnappinger D, et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding a-crystallin. Proceedings of the National Academy of Sciences, 2001. 98(13): p. 7534–7539.
[23] Keren I, Minami S, Rubin E, et al. Characterization and transriptome analysis of Mycobacterium tuberculosis persisters. MBio. 2011;2(3):e00100–11.
[24] Torrey HL, Keren I, Via LE, et al. High persister mutants in Mycobacterium tuberculosis. PLoS One. 2016;11(5):e0155127.
[25] Kapoor N, Pawar S, Sirakova TD, et al. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS One. 2013;8(1):e53567.
[26] Alonso S, Pethe K, Russell DG, et al. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Nat Acad Sci. 2007 104(14):6031–6036.
[27] Lin W, de Sessions PF, Teoh GHK, et al. Transcriptional profiling of mycobacterium tuberculosis exposed to in vitro lysosomal stress. Infect Immun. 2016;84(9):2505–2523.
[28] Lovewell RR, Sassetti CM, VanderVen BC. Chewing the fat: lipid metabolism and homeostasis during M. tuberculosis infection. Curr Opin Microbiol. 2016;29:30–36.
[29] Aguilar-Ayala DA, Tilleman L, Van Nieuwbergh F, et al. The transcriptome of Mycobacterium tuberculosis in a lipid-rich dormancy model through RNaseq analysis. Sci Rep. 2017;7(1):1–13.
[30] Kim MJ, Wainwright HC, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med. 2010;2(7):258–274.
[31] Mahajan S, Dkhar HK, Chandra V, et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARy and TR4 for survival. J Immunol. 2012;188(11):5593–5603.
[32] Dietzold J, Gopalakrishnan A, Salgame P. Duality of lipid mediators in host response against Mycobacterium tuberculos: good cop, bad cop. F1000prime reports, 2015. 7.
[33] Soto-Ramirez MD, Aguilar-Ayala DA, Garcia-Morales L, et al. Cholesterol plays a larger role during Mycobacterium tuberculosis in vitro dormancy and reactivation than previously suspected. Tuberculosis. 2017;103:1–9.
[34] Muñoz-Elias EJ, Upton AM, Cherian J, et al. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol. 2006;60(5):1109–1122.
[35] Forrellad MA, McNeil M, Santangelo MDLP, et al. Role of the Mcc1 transporter in the lipid homeostasis of Mycobacterium tuberculosis. Tuberculosis. 2014;94(2):170–177.
[36] Segal W. Growth dynamics of in vivo and in vitro grown mycobacterial pathogens. The mycobacteria. A sourcebook. New York, NY: Marcel Dekker, Inc; 1984. p. 547–573.
[37] Wheeler PR, Ratledge C, Metabolism of Mycobacterium tuberculosis. tuberculosis: pathogenesis, protection, and control, 1994: p. 353–385.
[38] Höner Zu Bentrup K, Miczak A, Swenson DL, et al. Characterization of activity and expression of isocitrate lyase in mycobacterium avium and mycobacterium tuberculosis. J Bacteriol. 1999;181(23):7161–7167.
[39] Wayne L, Lin K-Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun. 1982;37(3):1042–1049.
[40] McKinney JD, zu Bentrup KH, Muñoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406(6797):735–738.
[41] Dinadayala P, Lemassu E, Granovsky P, et al. Revisiting the structure of the anti-neoeplastic glucans of Mycobacterium bovis bacille calmette-guérin: structural analysis of the extracellular and boiling water extract-derived glucans of the vaccine substrains. J Biol Chem. 2004;279(13):12369–12378.
[42] Lemassu A, Daffé M. Structural features of the exacellular polysaccharides of Mycobacterium tuberculosis. Biochem J. 1994;297(2):351–357.
[73] Oh T-J, et al. Identification and characterization of Rv3281 as a novel subunit of a biotin-dependent acyl-CoA carboxylase in Mycobacterium tuberculosis H37Rv. J Biol Chem. 2006;281(7):3899–3908.

[74] Marquet A, Bui BTS, Florentin D. Biosynthesis of biotin and lipoic acid. Vitamins & Hormones. 2001;61:51–101.

[75] Mann S, Ploux O. 7, 8-Diaminoperargyl acid aminotransferase from Mycobacterium tuberculosis, a potential therapeutic target: characterization and inhibition studies. FEBS J. 2006;273(20):4778–4789.

[76] Mann S, Colliandre L, Labes G, et al. Inhibition of 7, 8-diaminoperargyl acid aminotransferase from Mycobacterium tuberculosis by chiral and achiral analogs of its substrate: biological implications. Biochimie. 2009 Jul 1;91(7):826–34.

[77] Mann S, Ploux O. Pyridoxal-5‘-phosphate-dependent enzymes involved in biotin biosynthesis: structure, reaction mechanism and inhibition. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2011 Nov 1;1814(11):1459–66.

[78] Woong Park S, Klotzsche M, Wilson DJ, et al. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 2011;7(9):e1002264.

[79] Sorci L, Pan Y, Eyobo Y, et al. Targeting NAD biosynthesis in bacterial pathogens: structure-based development of inhibitors of nicotinate mononucleotide adenylytransferase NaDd. Chem Biol. 2009;16 (8):849–861.

[80] Kim JH, O’Brien KM, Sharma R, et al. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Nat Acad Sci. [2013];110(47):19095–19100.

[81] Rodionova IA, Schuster BM, Guinn KM, et al. Metabolic and bactericidal effects of targeted suppression of NADd and NADe enzymes in mycobacteria. MBio. 2014;5(1):e00747–13.

[82] Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholestero. Proc Nat Acad Sci. 2008;105(11):4376–4380.

[83] Marrero J, Rhee KY, Schnappinger D, et al. Glucosoneogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Nat Acad Sci. 2010;107(21):9819–9824.

[84] Rhee KY, de Carvalho LP, Bryk R, et al. Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. Trends Microbiol. 2011;19(7):307–314.

[85] Muñoz-Elias EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med. 2005;11 (6):638–644.

[86] Muñoz-Elias EJ, McKinney JD. Carbon metabolism of intracellular bacteria. Cell Microbiol. 2006;8(1):10–22.

[87] Marrero J, Trujillo C, Rhee KY, et al. Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog. 2013;9(1): e1003116.

[88] Shi L, Sohaskey CD, Kana BD, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Nat Acad Sci. 2005;102 (43):15629–15634.

[89] Dhar N, McKinney JD. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc Nat Acad Sci. 2010;107 (27):12275–12280.

[90] Hu Y, Movahedzadeh F, Stoker NG, et al. Deletion of the Mycobacterium tuberculosis α-crystallin-like hspX gene causes increased bacterial growth in vivo. Infect Immun. 2006;74(2):861–868.

[91] Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa α-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Nat Acad Sci. 1998;95(16):9578–9583.

[92] Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton α-crystallin homolog. J Bacteriol. 1998;180(4):801–808.

[93] Yuan Y, Crane DD, Barry C 3rd. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol. 1996;178 (15):4484–4492.

[94] Verbon A, Hartseekel RA, Schuitema A, et al. The 14,000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J Bacteriol. 1992;174(4):1352–1359.

[95] Spratt JM, Britton WJ, Triccas JA. In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen. Bioengineered Bugs. 2010;1(1):61–65.

[96] Niu H, Hu L, Li Q, et al. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate M. tb10. 4–HspX. Vaccine. 2011;29 (51):9451–9458.

[97] Schnappinger D, Ehrt S, Voskuil MI, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med. 2003;198(5):693–704.

[98] Wilkinson KA, Stewart GR, Newton SM, et al. Infection biology of a novel α-crystallin of Mycobacterium tuberculosis: acr2. J Immunol. 2005;174(7):4237–4243.

[99] Manganelli R, Voskuil MI, Schoolnik GK, et al. The Mycobacterium tuberculosis ECF sigma factor σE: role in global gene expression and survival in macrophages. Mol Microbiol. 2001;41(2):423–437.

[100] Stewart GR, Snewin VA, Walzl G, et al. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med. 2001;7(6):732–737.

[101] Liberek K, Marszalek J, Ang D, et al. Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc Nat Acad Sci. 1991 88 (7):2874–2878.

[102] Grandvalet C, de Crecy-lagard V, Mazodier P, et al. The CtpB ATPase of Streptomyces albus G belongs to the HspR heat shock regulon. Mol Microbiol. 1999;31(2):521–532.

[103] Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med. 2003;198(5):705–713.
[104] Ohno H, Zhu G, Mohan VP, et al. The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol. 2003;5 (9):637–648.

[105] Monahan IM, Betts J, Banerjee DK, et al. Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology. 2001;147 (2):459–471.

[106] Shi L, Jung Y-J, Tyagi S, et al. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Nat Acad Sci. 2003;100(1):241–246.

[107] Drumm JE, Mi K, Bilder P, et al. Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-Binding: requirement for establishing chronic persistent infection. PLoS Pathog. 2009;5(5):e1000460.

[108] Singh A, Guidry L, Narasimhulu KV, et al. Mycobacterium tuberculosis WhiB3 responds to O2 and nitric oxide via its [4Fe-4S] cluster and is essential for nutrient starvation survival. Proc Nat Acad Sci. 2007;104(28):11562–11567.

[109] Mehta M, Rajmani RS, Singh A. Mycobacterium tuberculosis WhiB3 responds to vacuolar pH-induced changes in mycothiol redox potential to modulate phagosomal maturation and virulence. J Biol Chem. 2016;291(6):2888–2903.

[110] Steyn AJ, Collins DM, Hondalus MK, et al. Mycobacterium tuberculosis WhiB3 interacts with RpOV to affect host survival but is dispensable for in vivo growth. Proc Nat Acad Sci. 2002;99 (5):3147–3152.

[111] Cumming BM, Rahman MA, Lamprecht DA, et al. Mycobacterium tuberculosis arrests host cycle at the G1/S transition to establish long term infection. PLoS Pathog. 2017;13(5):e1006389.

[112] Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiol. 2012;7(4):513–518.

[113] Pawelczyk J, Brzostek A, Minias A, et al. Cholesterol-dependent transcriptome remodeling reveals new insight into the contribution of cholesterol to Mycobacterium tuberculosis pathogenesis. Sci Rep. 2021;11(1):1–16.

[114] Leistikow RL, Morton RA, Bartek IL, et al. The mycobacterium tuberculosis dosr regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J Bacteriol. 2010;192 (6):1662–1670.

[115] Taneja NK, Dhingra S, Mittal A, et al. Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C. PLoS One. 2010;5(5):e10860.

[116] Gautam US, Mehra S, Ahsan MH, et al. Role of TNF in the altered interaction of dormant Mycobacterium tuberculosis with host macrophages. PLoS One. 2014;9(4):e95220.

[117] Converse PJ, Karakousis PC, Klinkenberg LG, et al. Role of the dosR – dosS two-component regulatory system in mycobacterium tuberculosis virulence in three animal models. Infect Immun. 2009;77(3):1230–1237.

[118] Malhotra V, Sharma D, Ramanathan VD, et al. Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2004;231 (2):237–245.

[119] Mehra S, Foreman TW, Didier PJ, et al. The DosR Regulon Modulates Adaptive Immunity and Is Essential for Mycobacterium tuberculosis Persistence. Am J Respir Crit Care Med. 2015;191(10):1185–1196.

[120] Yang, H., W. Sha, and Z. Liu. Lysine acetylation of DosR regulates the hypoxia response of Mycobacterium tuberculosis. Emerg Microbes Infect. 2018;7(1):1–14.

[121] Gautam US, Mehra S, Kumari P, et al. Mycobacterium tuberculosis sensor kinase DosS modulates the autophagosome in a DosR-independent manner. Commun Biol. 2019;2(1):1–2.

[122] Rodrigue S, Provvedi R, Jacques P-E, et al. The σ factors of Mycobacterium tuberculosis. FEMS Microbiol Rev. 2006;30(6):926–941.

[123] Ando M, Yoshimatsu T, Ko C, et al. Deletion of Mycobacterium tuberculosis Sigma Factor E Results in Delayed Time to Death with Bacterial Persistence in the Lung of Aerosol-Infected Mice. Infect Immun. 2003;71(12):7170–7172.

[124] Casonato S, Provvedi R, Dainese E, et al. The extra cytoplasmic function sigma factor σ E is essential for mycobacterium tuberculosis virulence in mice. Infect Immun. 2004;72(5):3038–3041.

[125] Pando RH, Aguilar LD, Smith I, et al. Immunogenicity and protection induced by a mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect Immun. 2010;78(7):3168–3176.

[126] van de Weerd R, Boot M, Maaskant J, et al. Inorganic phosphate limitation modulates capsular polysaccharide composition in mycobacteria. J Biol Chem. 2016;291(22):11787–11799.

[127] Datta P, Shi L, Bibi N, et al. Regulation of central metabolism genes of mycobacterium tuberculosis by parallel feed-forward loops controlled by sigma factor σ E. J Bacteriol. 2011;193(5):1154–1160.

[128] Balázs G, Heath AP, Shi L, et al. The temporal response of the Mycobacterium tuberculosis gene regulatory network during growth arrest. Mol Syst Biol. 2008;4(1):225.

[129] Pisu D, Provvedi R, Espinosa DM, et al. The alternative sigma factors SigE and SigB are involved in tolerance and persistence to antitubercular drugs. Antimicrob Agents Chemother. 2017;61(12):e01596–17.

[130] Raman S, Song T, Puyang X, et al. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in mycobacterium tuberculosis. J Bacteriol. 2001;183(20):6119–6125.

[131] Graham JE, Clark-Curtiss JE, Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS).
Proceedings of the National Academy of Sciences. 1999 Sep 28;96(20):11554-9.

[133] Fontán P, Voskuil MI, Gomez M, et al. The mycobacterium tuberculosis sigma factor σ B is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth. J Bacteriol. 2009;191(18):5628–5633.

[134] Sherrid AM, Rustad TR, Cangello GA, et al. Characterization of a Cbp gene product regulator and the reaeration response in Mycobacterium tuberculosis. PLoS One. 2010;5(7):e11622.

[135] Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH. Proceedings of the National Academy of Sciences, 2002. 99(12): p. 8330–8335.

[136] Flynn JL. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 2006;8(4):1179–1188.

[137] Saukkonen JJ, Bazydlo B, Thomas M, et al. β-Chemokines are induced by mycobacterium tuberculosis and inhibit its growth. Infect Immun. 2002;70(4):1684–1693.

[138] Velmurugan K, Chen B, Miller JL, et al. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 2007;3(7):e110.

[139] Du P, Sohaskey CD, Shi L. Transcriptional and physiological changes during Mycobacterium tuberculosis reactivation from non-replicating persistence. Front Microbiol. 2016;7:1346.

[140] Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropenase synthetase is required for cording persistence, and virulence of Mycobacterium tuberculosis. Mol Cell. 2000;5(4):717–727.

[141] Corrales RM, Mollé V, Leiba J, et al. Phosphorylation of mycobacterial PcaA inhibits mycolic acid cyclopropanation: consequences for intracellular survival and for phagosome maturation block. J Biol Chem. 2012;287(31):26187–26199.

[142] Daniel J, Deb C, Dubey VS, et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol. 2004;186(15):5017–5030.

[143] Sirakova TD, Dubey VS, Deb C, et al. Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology. 2006;152(9):2717.

[144] Deb C, Lee C-M, Dubey VS, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One. 2009;4(6):e6077.

[145] Daniel J, Maamar H, Deb C, et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011;7(6): e1002093.

[146] Wilburn KM, Fieweger RA, VanderVen BC. Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis. Pathog Dis. 2018;76(2):fty021.

[147] Nesbitt NM, Yang X, Fontañá P, et al. A thiolase of mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun. 2010;78(1):275–282.

[148] Sundararajan S, Muniyan R. Latent tuberculosis: interaction of virulence factors in Mycobacterium tuberculosis. Mol Biol Rep. 2021;5:1–6.

[149] Dubnau E, Fontán P, Manganelli R, et al. Mycobacterium tuberculosis genes induced during infection of human macrophages. Infect Immun. 2002;70(6):2787–2795.

[150] Dubnau E, Chan J, Mohan VP, et al. Responses of mycobacterium tuberculosis to growth in the mouse lung. Infect Immun. 2005;73(6):3754–3757.

[151] Van der Geize R, Yam K, Heuser T, et al. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Nat Acad Sci. 2007;104(6):1947–1952.

[152] Hu Y, van der Geize R, Besra GS, et al. 3-Ketosteroid 9α,9β-dihydroxylase is an essential factor in the pathogenesis of mycobacterium tuberculosis. Mol Microbiol. 2010;75(1):107–121.

[153] Yam KC, D’Angelio I, Kalscheuer R, et al. Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog. 2009;5(3):e1000344.

[154] Chang JC, Miner MD, Pandey AK, et al. Igr Genes and mycobacterium tuberculosis cholesterol metabolism. J Bacteriol. 2009;191(16):5232–5239.

[155] Goodsmith N, Guo XV, Vandal OH, et al. Disruption of an M. tuberculosis membrane protein causes a magnesium-dependent cell division defect and failure to persist in mice. PLoS Pathog. 2015;11(2):e1004645.

[156] Buddelmeijer N, et al., YgbQ, a cell division protein in escherichia coli and vibrio cholerae, localizes in codependent fashion with FtsL to the division site. Proceedings of the National Academy of Sciences. 2002 Apr 30;99(9):6316-21.

[157] Levin PA, Losick R. Characterization of a cell division gene from Bacillus subtilis that is required for vegetative and sporulation septum formation. J Bacteriol. 1994;176(5):1451–1459.

[158] Wu KJ, Zhang J, Baranowski C, et al. Characterization of conserved and novel septal factors in Mycobacterium smegmatis. J Bacteriol. 2018;200(6):e00649–17.

[159] Wang R, Kreutzfeldt K, Botella H, et al. Persistent Mycobacterium tuberculosis infection in mice requires PerM for successful cell division. Elife. 2019;8:e49570.

[160] Vandal OH, Pierini LM, Schnappinger D, et al. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med. 2008;14(8):849–854.

[161] Botella H, Vaubourgeix J, Lee MH, et al. Mycobacterium tuberculosis protease MarP activates a peptidoglycan hydrolase during acid stress. EMBO J. 2017;36(4):536–548.

[162] Böth D, Schneider G, Schnell R. Peptidoglycan remodeling in Mycobacterium tuberculosis: comparison of
structures and catalytic activities of RipA and RipB. J Mol Biol. 2011;413(1):247–260.

[163] Martinelli DJ, Pavelka MS Jr, de Boer P. The RipA and RipB peptidoglycan endopeptidases are individually toxic to Mycobacterium smegmatis. J Bacteriol. 2016;198(9):1464–1475.

[164] Healy C, Gouzy A, Ehrt S. Peptidoglycan hydrolases RipA and Ami1 are critical for replication and persistence of Mycobacterium tuberculosis in the host. MBio. 2020;11(2):e00315–19.

[165] Hett EC, Chao MC, Steyn AJ, et al. A partner for the resuscitation-promoting factors of Mycobacterium tuberculosis. Mol Microbiol. 2007;66(3):658–668.

[166] Hett EC, Chao MC, Deng LL, et al. A mycobacterial enzyme essential for cell division synergizes with resuscitation-promoting factor. PLoS Pathog. 2008;4(2):e1000001.

[167] Kieser KJ, Boutte CC, Kester JC, et al. Phosphorylation of the peptidoglycan synthase PonA1 governs the rate of polar elongation in mycobacteria. PLoS Pathog. 2015;11(6):e1005010.

[168] Sharief M, Quadir N, Sharma N, et al. Mycobacterium tuberculosis RipA dampens TLR4-mediated host protective response using a multi-pronged approach involving autophagy, apoptosis, metabolic repurposing, and immune modulation. Front Immunol. 2021;12:434.

[169] Shi W, Zhang Y. PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65(6):1237–1242.

[170] Namugenyi SB, Aagesen AM, Elliott SR, et al. Mycobacterium tuberculosis PhoY proteins promote persister formation by mediating Pst/SenX3-RegX3 phosphate sensing. MBio. 2017;8(4):e00494–17.

[171] Rifat D, Bishai WR, Karakousis PC. Phosphate depletion: a novel trigger for Mycobacterium tuberculosis persistence. J Infect Dis. 2009;200(7):1126–1135.

[172] Tischler AD, Leistikow RL, Kirksey MA, et al. Mycobacterium tuberculosis requires phosphate-responsive gene regulation to resist host immunity. Infect Immun. 2013;81(1):317–328.

[173] Elliott SR, Tischler AD. Phosphate starvation: a novel signal that triggers ESX-5 secretion in Mycobacterium tuberculosis. Mol Microbiol. 2016;100(3):510–526.

[174] Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, et al. Diagnosis for latent tuberculosis infection: New alternatives. Frontiers in Immunology. 2020;11.

[175] Cho YS, Dobos KM, Prenni J, et al. Deciphering the proteome of the in vivo diagnostic reagent “purified protein derivative” from M ycobacterium tuberculosis. Proteomics. 2012;12(7):979–991.

[176] Pathakumari B, Devasundaram S, Raja A. Altered expression of antigen-specific memory and regulatory T-cell subsets differentiates latent and active tuberculosis. Immunology. 2018;153(3):325–336.

[177] Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-γ release assays among health-care workers in contact with patients with TB. Chest. 2012;142(6):1461–1468.

[178] Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77–87.

[179] Aggerbeck H, Gienzrz R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One. 2013;8(5):e64215.

[180] Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J. 2016;48(5):1411–1419.

[181] Petrucelli E, Vanini V, Chiachio T, et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis. 2017;106:38–43.

[182] Pourakbari B, Mamishi S, Benvari S, et al. Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-γ release assays: a systematic review and meta-analysis. Adv Med Sci. 2019;64(2):437–443.

[183] Chee CB, Gan SH, KhinMar KW, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol. 2008;46(6):1935–1940.

[184] de Araujo LS, da Silva NDBM, Leung J, et al. IgG subclasses’ response to a set of mycobacterial antigens in different stages of Mycobacterium tuberculosis infection. Tuberculosis. 2018;108:70–76.

[185] Chiliza TE, Pillay M, Naidoo K, et al. Immunoscreeing of the M. tuberculosis F15/LAM4/KZN secretome library against TB patients’ sera identifies unique active-and latent-TB specific biomarkers. Tuberculosis. 2019;115:161–170.

[186] Schuck SD, Mueller HH, Kunitz F, et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PloS One. 2009;4(5):e5590.

[187] Govender L, Abel B, Hughes EJ, et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine. 2010;29(1):51–57.

[188] Sable SB, Posey JE, Scriba TJ. Tuberculosis vaccine development: progress in clinical evaluation. Clin Microbiol Rev. 2019;33(1):e00100–19.

[189] Nandakumar S, Kannanganat S, Posey JE, et al. Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice. PLoS One. 2014;9(11):e113951.

[190] Dijkman K, Sombroek CC, Verveen RAW, et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019;25(2):255–262.

[191] Cruz A, Torrado E, Carmona J, et al. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4+IL-17+TNF +IL-2+ T cells. Vaccine. 2015;33(1):85–91.

[192] Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus calmette-guerin vaccination of newborns. Am J Respir Crit Care Med. 2010;182(8):1073–1079.
[193] Fletcher HA, Snowden MA, Landry B, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun. 2016;7(1):1.

[194] Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–480.

[195] Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus calmette-guérin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1.

[196] Soares AP, Kwong Chung CKC, Choice T, et al. Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis. 2013;207(7):1084–1094.

[197] Águlo N, Gonzalo-Asensio J, Alvarez-Arguedas S, et al. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat Commun. 2017;8(1):1.

[198] Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant Bacille Calmette–Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147.

[199] Grode L. Increased vaccine efficacy against tuberculosis of recombinant mycobacterium bovis bacille calmette-guérin mutants that secrete listeriolysin. J Clin Invest. 2005;115(9):2472–2479.

[200] Velmurugan K, Grode L, Chang R, et al. Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel). 2013;1(2):120–138.

[201] Hoft DF, Blazevic A, Selimovic A, et al. Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-naïve adults: a randomized, active-controlled, first-in-human phase 1 trial. EBioMedicine. 2016;7:278–286.

[202] Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013;31(9):1340–1348.

[203] Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vacc Immunol. 2017;24(2):e00439–16.

[204] Spertini F, Audran R, Chakour R, et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015;3(12):953–962.

[205] Cadena AM, Hopkins FF, Maiello P, et al. Concurrent infection with Mycobacterium tuberculosis confers robust protection against secondary infection in macaques. PLoS Pathog. 2018;14(10):e1007305.

[206] Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest. 2012;122(1):303–314.

[207] Darrah PA, Bolton DL, Lackner AA. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose mycobacterium tuberculosis challenge. J Immunol. 2014;193(4):1799–1811.

[208] Jeyanathan M, Shao Z, Yu X, et al. AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates. PloS One. 2015;10(8):e0135009.

[209] Sharpe SA, McShane H, Dennis MJ. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vacc Immunol. 2010;17(8):1170–1182.

[210] Billeskov R, Tan EV, Cang M, et al. Testing the H56 vaccine delivered in 4 different adjuvants as a BCG-booster in a non-human primate model of tuberculosis. PloS One. 2016;11(8):e0161217.

[211] Scriba TJ, Tameris M, Mansoor N, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40(1):279–290.

[212] Scriba TJ, Tameris M, Mansoor N, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203(12):1832–1843.

[213] Scriba TJ, Tameris M, Smit E, et al. A phase iiia trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or mycobacterium tuberculosis–infected adults. Am J Respir Crit Care Med. 2012;185(7):769–778.

[214] Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010;181(12):1407–1417.

[215] Kagina BM, Tameris MD, Geldenhuys H, et al. The novel tuberculosiis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses. Vaccine. 2014;32(45):5908–5917.

[216] Idoko OT, Owoh-Tai OA, Owiafe PK, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosiis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis. 2014;94(6):564–578.

[217] Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.

[218] Tameris M, Geldenhuys H, Luabeya AK, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PloS One. 2014;9(2):e87340.

[219] Nyendak M, Swarbrick GM, Duncan A, et al. Adenovirally-induced polyfunctional T cells do not necessarily recognize the infected target: lessons from a phase I trial of the AERAS-402 vaccine. Sci Rep. 2016;6(1):1–2.

[220] Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189–194.

[221] Lindenstrøm T, Knudsen NPH, Agger EM, et al. Control of chronic mycobacterium tuberculosis...
infection by CD4 KLRG1 – IL-2–secreting central memory cells. J Immunol. 2013;190(12):6311–6319.

[222] Woodworth JS, Aagaard CS, Hansen PR, et al. Protective CD4 T cells targeting cryptic epitopes of mycobacterium tuberculosis resist infection-driven terminal differentiation. J Immunol. 2014;192(7):3247–3258.

[223] Suliman S, Luabeya AKK, Geldenhuys H, et al. Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med. 2019;199(2):220–231.

[224] Penn-Nicholson A, Tameris M, Smit E, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med. 2018;6(4):287–298.

[225] Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7(7):e39215.

[226] Sharma SK, Katoch K, Sarin R, et al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep. 2017;7(1):1–2.

[227] Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and mycobacterium indicus pranii in tuberculosis pericarditis. N Engl J Med. 2014;371(12):1121–1130.

[228] Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci. 2004;9(1–3):1136–1156.

[229] Alluri KK, Reshma RS, Suraparaju R, et al. Synthesis and evaluation of 4', 5'-dihydropyripl aromatic [pyperidine-4, 7'-thieno [2, 3-c] pyran analogues against both active and dormant Mycobacterium tuberculosis. Bioorg Med Chem. 2018;26(8):1462–1469.

[230] Reshma RS, Yogeeswari P, Sriram D. Design and development of novel inhibitors for the treatment of latent tuberculosis. Int J Mycobacteriol. 2016;5:S121–S122.

[231] Sukheja P, Kumar P, Mittal N, et al. A novel small-molecule inhibitor of the mycobacterium tuberculosis demethylmenaquinone methyltransferase meng is bactericidal to both growing and nutritionally deprived persister cells. MBio. 2017;8(1):e02022–16.

[232] Fenholds G, Stevens L, Moses L, et al. In situ detection of mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect Immun. 2002;70(11):6330–6338.

[233] Keer J, Smelders MJ, Gray KM, et al. Mutants of Mycobacterium smegmatis impaired in stationary-phase survival The GenBank accession numbers for the sequences determined in this work are: AJ277088 (mutant 272A), AJ277089 (mutant 272E), AJ277990 (mutant 317C), AJ277152 (mutant 492A) and AJ276883 (mutant 391D). Microbiology. 2000;146(9):2209–2217.

[234] Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One. 2010;5(4):e10069.

[235] Aliabaud L, Alahari A, Trivelli X, et al. Temperature-dependent regulation of mycolic acid cyclopropanation in saprophytic mycobacteria: role of the Mycobacterium smegmatis 1351 gene (MSMEG_1351) in C5s-cyclopropanation of a-mycolates. J Biol Chem. 2010;285(28):21698–21707.

[236] Hu Y, Butcher PD, Mangan JA, et al. Regulation of hmp gene transcription in mycobacterium tuberculosis : effects of oxygen limitation and nitrosative and oxidative stress. J Bacteriol. 1999;181(1):3486–3493.

[237] Vandal OH, Roberts JA, Odaire T, et al. Acid-susceptible mutants of mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009;191(2):625–631.

[238] Pham TV, Murkin AS, Moynihan MM, et al. Mechanism-based inactivator of isocitrate lyase 1 and 2 from Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences. 2017. 114(29): p. 7617–7622.

[239] Bhusal RP, Basheer G, Kawai B, et al. Targeting isocitrate lyase for the treatment of latent tuberculosis. Drug Discov Today. 2017;22(7):1008–1016.

[240] Saxena S, Devi PB, Soni V, et al. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (M. TB-AdaDh) through structure-based virtual screening. J Mol Graphics Modell. 2014;47:37–43.

[241] Dutta NK, Klinkenberg LG, Vazquez M-J, et al. Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence. Sci Adv. 2019;5(3):eaat2104.

[242] Capodagli GC, Sedhom WG, Jackson M, et al. A noncompetitive inhibitor for mycobacterium tuberculosis's class iia fructose 1,6-bisphosphate aldolase. Biochemistry. 2014;53(1):202–213.

[243] Daher R, Coinçon M, Fonvielle M, et al. Rational design, synthesis, and evaluation of new selective inhibitors of microcrystalline class ii (zinc dependent) fructose bis-phosphate aldolase. J Med Chem. 2010;53(21):7836–7842.

[244] Park SW, Casalena D, Wilson D, et al. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem Biol. 2015;22(1):76–86.

[245] Eiden CG, Aldrich CC. Synthesis of a 3-Amino-2, 3-dihydropyridin-4-one and related heterocyclic analogues as mechanism-based inhibitors of BioA, a pyridoxal phosphate-dependent enzyme. J Org Chem. 2017;82 (15):7806–7819.

[246] Singh S, Khare G, Bahal RK, et al. Identification of Mycobacterium tuberculosis BioA inhibitors by using structure-based virtual screening@. Drug Des Devel Ther. 2018;12:1065.

[247] Wang X, Ahn Y-M, Lentscher AG, et al. Design, synthesis, and evaluation of substituted nicotinamide adenosine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents. Bioorg Med Chem Lett. 2017;27(18):4426–4430.

[248] Gupta RK, Thakur TS, Desiraju GR, et al. Structure-based design of deacetyl inhibitor active against nonreplicating mycobacterium tuberculosis. J Med Chem. 2009;52(20):6324–6334.

[249] Zheng H, Colvin CJ, Johnson BK, et al. Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. Nat Chem Biol. 2017;13 (2):218–225.